



Vanta Bioscience Limited



**3rd Annual Report
F.Y. 2018-19**

CORPORATE INFORMATION**Board of Directors**

Mr. Mulakala Mohan Krishna	: Chairman (Non - Executive)
Mr. Mulakala Dopesha Raja	: Managing Director
Mr. S Venkata Rao	: CEO & Whole Time Director
Dr. Vyasmurti Madhavrao Shingatgeri	: Whole Time Director
Dr. Padmanabhuni Venkata Appaji	: Independent Director
Dr. Gonuguntla Kathyayani	: Independent Director
Dr. Yogeshwara Rao Danda	: Independent Director

KMP

Mr. A. Kiran Kumar	: Chief Financial Officer
Mr. Zoheb S Sayani	: Company Secretary and Compliance Officer

Registered Office**Vanta Bioscience Limited**

No.02/G/308/G, No.3/FF/SF/1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, Telangana, India
CIN: L74999TG2016PLC109280| Website: www.vantabio.com
Contact No.: +91 40 6657 5454|Email ID: cs@vantabio.com

Statutory Auditors**Mathesh & Ramana**

Chartered Accountants
3-6-145, Himayatnagar, Hyderabad - 500029

Corporate Consultants**Tapasvilal Deora & Associates**

Practising Company Secretaries
Office No. 404(2), Paigah Plaza, Basheerbagh, Hyderabad - 500 063, T.S.
Email ID: cstapasvideora@gmail.com

Bankers**State Bank of India**

SME Branch, Saifabad, Hyderabad - 500004

Registrar & Share Transfer Agents**Bigshare Services Private Limited**

306, Right Wing, Amrutha Ville Apts. Somajiguda, Hyderabad - 500 082
Contact No. : 040 2337 4967; E-Mail : prabhakar@bigshareonline.com

Listed at

SME Platform of BSE Ltd.

VANTA BIOSCIENCE LIMITED

Regd. Office: No.02/G/308/G, No.3/FF/SF/1-20-248, Umajay Complex, Rasoolpura,
Secunderabad – 500 003, Telangana, India

CIN: L74999TG2016PLC109280| **Website:** www.vantabio.com

Contact No.: +91 40 6657 5454| **Email ID:** cs@vantabio.com

NOTICE

NOTICE IS HEREBY GIVEN THAT THE THIRD ANNUAL GENERAL MEETING OF THE MEMBERS OF VANTA BIOSCIENCE LIMITED WILL BE HELD ON FRIDAY, SEPTEMBER 27, 2019 AT 11.00 A.M. AT TWILIGHT, 6TH FLOOR, MANASAROVAR THE FERN - AN ECOTEL, U.S. CONSULATE LANE, BEGUMPET, SECUNDERABAD 500003, TELANGANA

Ordinary Business

1. To receive, consider and adopt the Standalone Audited Financial Statements for the financial year ended March 31, 2019 along with the Reports of the Auditors and Board of Directors thereon.
2. To receive, consider and adopt the Consolidated Audited Financial Statements for the financial year ended March 31, 2019 together with the Report of the Auditors thereon.
3. To appoint a Director in place of Mr. Sadhanala Venkata Rao(DIN: 02906370) who retires by rotation and being eligible, offers himself for re-appointment.

Special Business

4. Appointment of Dr. Yogeswara Rao Danda as an Independent Director

To consider and, if thought fit, to pass with or without modification, the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 (the "Act") , the Companies (Appointment and Qualifications of Directors) Rules, 2014, read with Schedule IV of the Act and pursuant to applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), as amended from time to time, Dr. Yogeswara Rao Danda, (DIN: 00694803) who was appointed as an Additional Director of the Company with effect from May 22, 2019 and who holds office up to the date of this Annual General Meeting of the Company in terms of Section 161(1) of the Act and in respect of whom the Company has received a notice in writing from a member under Section 160(1) of the Act proposing his candidature for the office of Director of the Company, be and is hereby appointed as Director of the Company under Independent Category, not liable to retire by rotation, for a term of five (5) consecutive years commencing from May 22, 2019 upto May 21, 2024.

RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorized to do all such acts, deeds and things as may be required to give effect to the above resolution."

**By order of the Board
for VANTA BIOSCIENCE LIMITED**

**Sd/-
SADHANALA VENKATA RAO
CEO & WHOLE TIME DIRECTOR
DIN: 02906370**

August 27, 2019
Secunderabad

NOTES:

1. The relative explanatory statement pursuant to Section 102 of the Companies Act, 2013, in respect of the business under Item No.4 of the Notice, is annexed hereto. The relevant details pursuant to Regulations 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**"LODR Regulations"**) and as required under Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Directors seeking appointment/ reappointment at this Annual General Meeting (**"AGM"**) are also annexed.
2. **A MEMBER ENTITLED TO ATTEND AND TO VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND SUCH A PROXY NEED NOT BE A MEMBER OF THE COMPANY.** A person can act as proxy on behalf of Members not exceeding fifty and holding in the aggregate not more than ten percent (10%) of the total share capital of the Company carrying voting rights. A Member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as proxy for any other person or shareholder.
3. **A Proxy form is enclosed herewith. Proxy(ies) in order to be effective must submit proxy form at the company's registered office not less than 48 hours before the commencement of the meeting.**
4. Corporate members intending to send their authorized representatives to attend the meeting are requested to send to the Company a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the meeting.
5. Members holding shares in dematerialized form are advised to inform the particulars of change of address and email ids to their respective Depository Participants only. The Company or its Registrar and Transfer Agents cannot act on any request received directly from the members holding shares in dematerialized mode for such changes and such instructions shall be given directly to the Depository Participants by the members.
6. Copies of notice of the AGM are being sent by electronic mode to those members whose email ids are available with our Registrar and Transfer Agents, unless members have requested for physical copy specifically. For members whose e-mail ids are not available, physical copy is being sent by permitted mode. The complete annual report is also available on the website of the company: www.vantabio.com.
7. Pursuant to Section 108 of Companies Act, 2013 read with rules made thereunder and Regulation 44 of the SEBI (LODR) Regulations, 2015, the Company is providing e-voting facility to its Members to exercise their votes electronically on the item of business given in the Notice through the electronic voting service facility provided by CDSL.
8. Members can opt for only one mode of voting i.e. either by physical ballot paper or remote e-voting. However, if members cast their vote through both modes of voting, then the voting through remote e-voting shall prevail. The members who have cast their vote by remote e-voting may also attend the AGM but shall not be entitled to cast their vote again. Also the facility for voting, ballot or polling paper shall (as the case may be) will be made available at the meeting and members attending the meeting who have not already cast their vote by remote e-voting shall be able to exercise their right at the meeting;
9. Subject to the receipt of requisite number of votes, the resolution shall be deemed to be passed at the AGM. The result declared, along with the Scrutinizer's Report, will be placed on the Company's website after the result is declared by the Chairman or any other person authorized by the Chairman, and the same shall be communicated to the BSE Ltd.

THE INSTRUCTIONS FOR SHAREHOLDERS VOTING ELECTRONICALLY ARE AS UNDER:

- I. The voting period begins on September 24, 2019 at 9:00 AM and ends on September 26, 2019 at 5:00 PM. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date - September 20, 2019 may cast their vote electronically and that a person who is not a member as on the cut-off date should treat this notice for information purposes only. The e-voting module shall be disabled by CDSL for voting thereafter.
- II. The shareholders should log on to the e-voting website www.evotingindia.com.
- III. Click on Shareholders.
- IV. Now Enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
- V. Next enter the Image Verification as displayed and Click on Login.
- VI. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- VII. If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders). - Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field. - In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iv).

- VIII. After entering these details appropriately, click on "SUBMIT" tab.
- IX. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

VANTA BIOSCIENCE LIMITED

- X. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- XI. Click on the EVSN for Vanta Bioscience Limited.
- XII. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- XIII. Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- XIV. After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- XV. Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- XVI. You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- XVII. If a demat account holder has forgotten the login password, then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- XVIII. Shareholders can also cast their vote using CDSL’s mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Please follow the instructions as prompted by the mobile app while voting on your mobile.
- XIX. Any person, who acquires shares of the Company and become Member of the Company after dispatch of the Notice and holding shares as on the cut-off date may follow the same instructions as mentioned above for remote e-Voting or sending a request at helpdesk.evoting@cdslindia.com
- XX. Note for Non – Individual Shareholders and Custodians
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporates.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- XXI. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com or to the Company at cs@vantabio.com.
- XXII. The Company has appointed Mr. Tapasvilal Deora, Company Secretary in Practice as “Scrutinizer” for conducting the e-voting process for the Annual General Meeting in a fair and transparent manner.
- XXIII. Shareholders who have not registered their email id and wish to receive all communications/correspondences in electronic form can submit their request in the format annexed to this Annual Report. For any queries, please write to cs@vantabio.com.

EXPLANATORY STATEMENT

As required under Section 102 of the Companies Act, 2013 ("Act"), the following explanatory statement sets out all material facts relating to business mentioned under Item No.4 of the accompanying Notice:

Item No.4

The Board of Directors, on the recommendation of the Nomination and Remuneration Committee, appointed Dr. Yogeswara Rao Danda, (DIN: 00694803) as an Additional Director under Independent Category on May 22, 2019.

The following is the brief Profile of Dr. Yogeswara Rao Danda

Dr. Yogeswara Rao Danda is currently a visiting professor at University of Hyderabad for Innovation and entrepreneurship. He is also a consultant to CSIR-IICT. He served as Adviser at the office of Principal Scientific Adviser to Government of India, New Delhi before superannuation. Previous to that, he served Council of Scientific and Industrial Research (CSIR) for over 25 years in different capacities.

He has a Masters' degree in Chemistry from Andhra University and Ph.D degree from Indian Institute of Technology, Bombay in chemistry. Before joining CSIR in 1988 he worked with industry for over six and half years.

Dr. Rao was associated with Science, Technology and Innovation for large part of his career, besides encouraging knowledge-based entrepreneurship. He has expertise in R&D management with interests in R&D Planning, Technology assessment, transfer and entrepreneurship, besides organisational policies. He specializes in building multi-institutional and industry network projects.

His ability coupled with innate leadership qualities has led him to develop two successful R&D programmes at the national level viz. (i) New Millennium Indian Technology leadership Initiative (NMITLI) and (ii) Promotion of R&D in the Drugs and Pharmaceuticals sector. Dr. Rao is an active proponent of the Public-Private-Partnership programmes in R&D domain and implemented several R&D projects in PPP mode.

During his long and eventful career, he evolved several enabling organizational policies including the cabinet note on Scientist Entrepreneur scheme that permitted scientists to setup companies while in service.

He was a director in Association for Scientific Pursuits for Innovative Research Enterprises (ASPIRE), Lee Pharma Limited and Biovet Private Limited.

The Board considers that his association would be of immense benefit to the Company and it is desirable to appoint him as Independent Director of the Company.

The Company has also received a declaration from Dr. Yogeswara Rao Danda, that he meets the criteria of independence as prescribed under Section 149 of the Act and the LODR Regulations.

In the opinion of the Board, Dr. Yogeswara Rao Danda, meets the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) and other applicable provisions of the LODR Regulations. Dr. Yogeswara Rao Danda, is not disqualified from being appointed as Directors in terms of Section 164 of the Act and has consented to act as Independent Director of the Company. In the opinion of the Board he is a person of integrity and possesses relevant expertise and experience. Further, he fulfils the conditions specified in the Act and the LODR Regulations for appointment as an Independent Director and is independent of the Management of the Company and he is not debarred from accessing the capital markets and/or restrained from holding position of directors in any listed company.

VANTA BIOSCIENCE LIMITED

In compliance with the provisions of Section 149 read with Schedule IV of the Act and applicable provisions of LODR Regulations, the appointment of Dr. Yogeswara Rao Danda as an Independent Director with effect from May 22, 2019 for a period of five (5) consecutive years is now being placed before the Members for their approval as an ordinary resolution.

The terms and conditions of his appointment shall be open for inspection by the Members at the Registered Office of the Company during the normal business hours on any working day (except Saturday) and will also be kept open at the venue of the AGM till the conclusion of the AGM. Further details of Dr. Yogeswara Rao Danda have been given in the Annexure to this Notice.

The Board recommends the Resolution at Item No. 4 of this Notice for approval of the Members.

None of the Directors or Key Managerial Personnel or their respective relatives other than Dr. Yogeswara Rao Danda is concerned or interested in the Resolution at Item No. 4 of the Notice.

**By order of the Board
For Vanta Bioscience Limited**

**Sd/-
Sadhanala Venkata Rao
CEO & Whole Time Director
DIN: 02906370**

**August 27, 2019
Secunderabad**

ANNEXURE TO NOTICE

Details of Directors seeking appointment / re-appointment in forthcoming Annual General Meeting (In pursuance of Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings)

Name of Director	Mr. Sadhanala Venkata Rao	Dr. Yogeswara Rao Danda
Director Identification Number (DIN)	02906370	00694803
Date of Birth	25/12/1963	09/02/1955
Age	55 Years	64 Years
Qualifications	CA, CS, B.Com from University of Calcutta	Phd, IIT Bombay
Experience	29 Years	More than 35 Years
Terms and Conditions of Appointment	Liable to retire by rotation. Offered himself for reappointment He is the CEO & Whole Time Director of the Company appointed by the Board and approved by the shareholders of the Company	Terms and conditions of appointment are as per the resolution at Item No 4 of the Notice convening Annual General Meeting on September 27, 2019 read with explanatory statement thereto.
Remuneration last Drawn	Rs. 30,00,000/-	As an Independent Director, he is entitled to sitting fees for attending meetings of the Board/ Committee and Commission as may be approved by the Board of Directors from time to time.
Nature of Expertise in specific functional areas	He has experience of over 25 years in fund raising, strategy turnaround, mergers and acquisitions, project management and project finance.	Biotechnology, Bioinformatics, Life sciences, Research & Development, Chemistry and Product Development
Date of 1st Appointment	February 07, 2018	May 22, 2019
Number of shares held in the Company	Nil	Nil
Inter-se relationship with other Directors and Key Managerial Personnel	Not related to any other Directors and Key Managerial Personnel	Not related to any other Directors and Key Managerial Personnel
No of Board Meetings Attended during the year	9 out of 9	Not applicable. He is appointed w.e.f. May 22, 2019
Directorships held in other companies (excluding foreign companies and Vanta Bioscience Limited)	• Vanta Clinical Research Limited • Vayam Research Solutions Limited	• Association for Scientific Pursuits for Innovative Research Enterprises (ASPIRE), • Lee Pharma Limited • Biovet Private Limited
Membership/ Chairmanships of committees of other companies (includes only Audit Committee and Stakeholders Relationship)	Nil	Nil

DIRECTOR'S REPORT

Dear Members,

Your Directors have pleasure in presenting herewith the 3rd Annual Report on the business of the Company together with the Financial Statements for the financial year ended March 31, 2019.

OUR BUSINESS

Vanta Bioscience Limited (VBS) is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, we also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.

FINANCIAL HIGHLIGHTS

The following are the financial highlights of the Company:

(Amount in Rs.)

PARTICULARS	Standalone Basis		Consolidated Basis
	31.03.2019	31.03.2018	31.03.2019*
Total Revenue	12,65,36,666	4,03,87,179	12,65,36,666
Total Expenses	11,55,60,585	3,72,37,602	11,55,05,005
Profit before Tax	1,09,76,081	31,49,577	1,10,31,661
Current Tax	22,89,357	6,00,152	23,03,808
Deferred Tax	17,49,145	22,76,497	17,49,145
Profit after Tax	69,37,578	2,72,928	69,78,707
Less:Minority Interest	0	0	13,915
Profit	69,37,578	2,72,928	69,64,792

• This year being the First year on Consolidation Basis, figures only for the Year ended 31.03.2019 have been provided..

DIVIDEND

The Board has not recommended any dividend for the financial year 2018-19.

TRANSFER TO RESERVES

No amount has been transferred to general reserves during the year under review. Reserves and Surplus are disclosed in Note 4 of the financial statements.

DEPOSITS

The Company has neither accepted nor renewed any deposits from public as defined under the provisions of Companies Act, 2013 and Companies (Acceptance of Deposits) Rules, 2014.

SUBSIDIARIES:

During the year under review, the Company has incorporated two (2) subsidiary companies in the name of Vanta Clinical Research Limited and Vayam Research Solutions Limited. Details of the same are given below:

➤ **Vanta Clinical Research Limited (VCRL)**

VCRL was incorporated as a Wholly Owned Subsidiary of Vanta Bioscience Limited on September 12, 2018 with the object of dealing in the business of Research & Development in the field of discovery and development of drugs, biologicals, vaccines, gene-based therapies in vitro, ex-vivo and in vivo techniques for screening and evaluation of drugs, dermaticals and cosmetics, clinical data management, statistical analysis, pharmacovigilance, medical writing, bio informatics, computer-aided drug designing, biotechnology, life sciences, diagnostic services and such other similar activities.

The paid up capital of VCRL as on March 31, 2019 was Rs. 2,00,00,000/-. The total revenue earned during the year was Rs. 3,50,000/- as against a total expenditure of Rs. 3,40,851/-.

The Profit after tax was Rs. 12,731/-.

VCRL is a 100% subsidiary of our Company and has contributed an amount of Rs. 12,731/- to the overall performance of the Company.

➤ **Vayam Research Solutions Limited (VRSL)**

VRSL was incorporated as a 51% Subsidiary of VCRL on October 10, 2018 with the object of carrying business of providing research and development, full range of clinical studies in the areas of pharmaceuticals industry, agro, chemical, food cosmetics and medical devices. Accordingly, VRSL is a step down subsidiary of Vanta Bioscience Limited.

The Company has purchased the assets from Emcure Pharmaceuticals Limited, Pune by way of an "Agreement for Sale of Goods and Equipment" dated April 04, 2019. The Company will start conducting Bioequivalence studies from the site, as soon as DCGI's approval is obtained.

The paid up capital of VRSL as on March 31, 2019 was Rs. 2,00,00,000/-. The total revenue earned during the year was Rs. 4,50,000/- as against a total expenditure of Rs. 4,11,624/-.

The Profit after tax was Rs. 28,398/-.

VRSL is a step down subsidiary of our Company and has contributed an amount of Rs. 14,483/- to the overall performance of the Company.

The Statement containing the salient features of the subsidiaries as per sub-sections (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014 of the Companies Act 2013 in Form AOC-1 is herewith annexed as Annexure-I to this report.

The Annual Report of the Company, containing therein its standalone and the consolidated financial statements has been placed on the website of the Company www.vantabio.com. Further, audited annual accounts of each of the subsidiary companies have also been placed on the website of the Company. Shareholders interested in obtaining a physical copy of the audited annual accounts of the subsidiary companies may write to the Company Secretary requesting for the same.

There were no associates or joint ventures of the Company as on the end of financial year March 31, 2019. There were no companies which have ceased to be our subsidiaries, joint ventures or associate companies during the financial year 2018-19.

Vanta Clinical Research Limited and Vayam Research Solutions Limited have become subsidiaries of our Company during the year under review.

DETAILS OF DIRECTORS

In accordance with the provisions of Section 152 of the Companies Act, 2013 and Articles of Association of the Company, Mr. Sadhanala Venkata Rao (DIN: 02906370), CEO & Whole Time Director of the Company is liable to retire by rotation, being eligible offers himself for re-appointment.

During the year under review, there were no changes that took place on the Board of the Company.

The following changes took place after the financial year March 31, 2019 upto the date of this Annual Report:

S. No	Name of the Director	Type of Change	W.e.f
1	Dr. Jang Bahadur Gupta (DIN 07751205)	Resignation as Independent Director	May 22, 2019
2	Dr. Yogeswara Rao Danda (DIN 00694803)	Appointment as Additional Director under Independent Category	May 22, 2019

INDEPENDENT DIRECTORS:

The Independent Directors of the Company have given the declaration and confirmation to the Company as required under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 confirming that they meet the criteria of independence and that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

DETAILS OF KEY MANAGERIAL PERSONNELS

During the year under review, Mr. Kiran Kumar Annabatula was appointed as Chief Financial Officer of the Company w.e.f July 04, 2018.

Accordingly, Mr. Dopesh Raja Mulakala, Managing Director (DIN: 01176660), Mr. Sadhanala Venkata Rao, CEO & Whole Time Director (DIN:02906370), Dr. Vyasmurti Madhavrao Shingatgeri, Whole Time Director (DIN: 07728757) Mr. Kiran Kumar Annabatula, Chief Financial Officer and Mr. Zoheb Sultan Ali Sayani, Company Secretary are Key Managerial Personnels of the Company.

Except as stated hereabove, there were no other appointments or resignations of key managerial personnels during the year under review.

MEETINGS OF THE BOARD AND COMMITTEES

During the year under review, Nine (9) Board Meetings, five (5) Audit Committee meetings, two (2) Nomination and Remuneration Committees and two (2) Stakeholders Relationship Committee meeting were held.

The Board and committee meetings of the Company were held in compliance with all the applicable provisions of the Companies Act, 2013, SEBI (LODR) Regulations, 2015 and the secretarial standards.

An extra ordinary general meeting of members was held on September 29, 2018 for obtaining the approval of shareholders for issue of 13,74,000 equity shares of Rs. 10/- each on preferential basis.

BOARD EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board evaluated the effectiveness of its functioning and that of the Committees and of individual directors by seeking their inputs on various aspects of Board/Committee Governance.

The aspects covered in the evaluation included the contribution to and monitoring of corporate governance practices, participation in the long-term strategic planning and the fulfilment of Directors' obligations and fiduciary responsibilities, including but not limited to, active participation at the Board and Committee meetings. The Chairman of the Board had one-on-one meetings with the Independent Directors. These meetings were intended to obtain Directors' inputs on effectiveness of Board/Committee processes. Further, the Independent Directors at their meeting, reviewed the performance of Board, Chairman of the Board and of Non-Executive Directors.

STATUTORY AUDITORS

M/s. Mathesh & Ramana, Chartered Accountants (FRN 002020S) were appointed as the statutory auditors of the Company by the members in their 2nd AGM held on August 21, 2018 for a period of 5 years from the conclusion of the 2nd Annual General Meeting of the Company held on August 21, 2018 till the conclusion of 7th Annual General Meeting.

AUDITORS' REPORT

The Auditors' Report does not contain any qualification. Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments.

There were no frauds reported by the Statutory Auditors of the Company during the year under review.

SECRETARIAL AUDIT REPORT

Tapasvilal Deora & Associates, Practicing Company Secretary were appointed to conduct the secretarial audit of the Company for the financial year 2018-19, as required under Section 204 of the Companies Act, 2013 and rules there-under. The secretarial audit report for FY 2018-19 forms part of this Annual Report as Annexure - II.

The Report contains a qualification and managements' reply is given below

S. No.	Particulars	Managements' Reply
1	There were certain discrepancies/lapses in compliance with erstwhile Regulation 72(2) and certain other provisions of erstwhile Chapter VII SEBI (ICDR) Regulations, 2009 in connection with preferential issue. (currently Chapter V of SEBI (ICDR) Regulations, 2018)	The said lapse has occurred as the said subscribers did not provide the requisite information to the Company. Accordingly, shares were not allotted to these shareholders under preferential issue. Subsequently, the matter was resolved and the Company received necessary approvals from BSE Ltd, NSDL and CDSL.

There are no other observations, qualifications or remarks in the report and is self-explanatory and do not call for any further comments.

CHANGES IN THE AUTHORIZED AND PAID UP CAPITAL

The Authorized Share Capital of the Company is Rs. 7,50,00,000/- (Rupees Seven Crore and Fifty Lakhs only). During the year under review, there was no change in the authorized share capital of the Company.

During the year under review, the shareholders of the Company in their EGM held on September 29, 2018 approved preferential issue of 13,74,000 equity shares of Rs.10/- at a premium of Rs. 75/- to Promoters and Non Promoters in accordance with the provisions of the Companies Act, 2013 and the SEBI (ICDR) Regulations. Subsequently, the Board of Directors of the Company in their meeting held on November 28, 2018 approved the allotment of 5,84,000 equity shares of Rs. 10/- each to Promoter and Non Promoters.

Accordingly, the paid up capital of the Company as at the end of the financial year was Rs.6,31,20,000/- (Rupees Six Crore Thirty-One Lakh and Twenty Thousand Only) comprising of 63,12,000 (Sixty Three Lakh and Twelve Thousand) equity shares of Rs. 10/- (Rupees Ten Only) each.

UTILIZATION OF PROCEEDS FROM PREFERENTIAL ISSUE,

The Company during the year issued 5,84,000 equity shares of Rs. 10/- each at a premium of Rs. 75/- on preferential basis and their utilization is as follows: - (Amount In Lakhs)

Proceeds from Preferential Allotment	496.40
Utilization	
Investment in Subsidiary	200.00
General Corporate & Working Capital	76.40
Issue Expenses	25.00
Balance -Investment in liquid funds	195.00
Total	496.40

AUDIT COMMITTEE

The Audit Committee was re-constituted at the meeting of the Board dated May 22, 2019. The Audit Committee comprises of:

Name of Director	Status in Committee	Nature of Directorship
Dr. Padmanabhuni Venkata Appaji	Chairman	Independent Director
Dr. Yogeswara Rao Danda	Member	Independent Director
Mr. Dopesha Raja Mulakala	Member	Managing Director

The Committee inter alia reviews the Internal Control System, Reports of Internal Auditors and Compliance of various regulations. The Committee also reviews the financial statements before they are placed before the Board. The Board of Directors of the Company have accepted all the recommendations given by the Audit Committee.

STAKEHOLDERS' RELATIONSHIP COMMITTEE

The Stakeholders' Relationship Committee at the meeting of the Board dated May 22, 2019. The Stakeholders' Relationship Committee comprises of:

Name of Director	Status in Committee	Nature of Directorship
Dr. Padmanabhuni Venkata Appaji	Chairman	Independent Director
Dr. Yogeswara Rao Danda	Member	Independent Director
Mr. Dopesha Raja Mulakala	Member	Managing Director

NOMINATION AND REMUNERATION POLICY

A committee of the Board has been formed which is named as "Nomination and Remuneration Committee" which has been entrusted with the task to recommend a policy of the Company on Directors' appointment and remuneration, including criteria for determining qualifications, positive attributes, independence of a Director and other matters and to frame proper systems for identification, appointment of Directors & KMPs, Payment of Remuneration to them and evaluation of their performance and to recommend the same to the Board from time to time. Nomination and Remuneration Policy of the Company is enclosed herewith as Annexure - III.

The Nomination and Remuneration Committee was re-constituted at the meeting of the Board dated May 22, 2019 and include the following:

Name of Director	Status in Committee	Nature of Directorship
Dr. Yogeswara Rao Danda	Chairman	Independent Director
Dr. Padmanabhuni Venkata Appaji	Member	Independent Director
Dr. Kathyayani Gonuguntla	Member	Independent Director

CORPORATE SOCIAL RESPONSIBILITY

The provisions of Section 135 of the Companies Act, 2013 in connection with corporate social responsibility are not applicable to the Company.

VIGIL MECHANISM

Pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013 and the applicable SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Vigil Mechanism or Whistle-Blower Policy for directors, employees and other stakeholders to report genuine concerns has been established. The same is also uploaded on the website of the Company - www.vantabio.com

RISK MANAGEMENT POLICY

The Risk Management is overseen by the Audit Committee of the Company on a continuous basis. The Committee oversees Company's process and policies for determining risk tolerance and review management's measurement and comparison of overall risk tolerance to established levels. There are no material risks which threaten the very existence of the company.

INTERNAL FINANCIAL CONTROLS

The Company has adequate internal financial controls which commensurate with the size of the business of the Company.

The Board has appointed M/s. K B S & Associates., Chartered Accountants (FRN 011208S) as the Internal Auditors of the Company for conducting the Internal Audit of the Company for a period of 3 financial years i.e. from the financial year 2017 - 2018 till the financial year 2019-2020.

DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to Section 134 (5) of the Companies Act, 2013 Your Directors' confirm that:

- i. in preparation of annual accounts for the financial year ended March 31, 2019 the applicable accounting standards have been followed along with proper explanation relating to material departures;
- ii. the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year ended March 31, 2019 and of the profit and loss of the Company for the year;
- iii. the Directors have taken proper and sufficient care for their maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv. the Directors had prepared the annual accounts on a going concern basis;
- v. the Directors, had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.
- vi. the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE OUTGO

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is enclosed herewith as Annexure-IV.

EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in Form MGT-9 is annexed herewith as Annexure -V.

PARTICULARS OF EMPLOYEES

Pursuant to Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, during the financial year no employee was in receipt of remuneration of Rs. 1.02 Crore or more, or where employed for part of the year was in receipt of Rs. 8.5 Lakh or more a month.

VANTA BIOSCIENCE LIMITED

Disclosure under Rule 5 of the Companies(Appointment & Remuneration of Managerial Personnel) Rules, 2014 is enclosed as Annexure - VI.

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis Report as required under Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure - VII to this report.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

During the year under review, the Company has not granted any Loans or given guarantees under Section 186 of the Companies Act, 2013.

The Company has investment in mutual funds. Further, the Company has invested in its Wholly Owned Subsidiary - Vanta Clinical Research Limited. Details of the same are disclosed in Note 12 and 14 of the financial statements.

LISTING ON SME PLATFORM OF BSE

Pursuant to the initial public offering, the equity shares of the Company were listed on the SME Platform of BSE Ltd w.e.f October 06, 2017 vide BSE Notice 20171005-33 dated October 05, 2017. The Company confirms that the annual listing fees to the stock exchanges for the financial year 2019-20 have been paid.

COST RECORDS

The provisions of cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013 are not applicable to the Company.

RELATED PARTY TRANSACTIONS

There were no materially significant related party transactions with the Company's Promoters, Directors, Management or their relatives, which could have had a potential conflict with the interests of the Company. All related party transactions entered by the Company under Section 188 of the Companies Act, 2013 are at arm's length. These related party transactions have been entered considering the business requirements, administrative convenience and in the best interest of the Company.

The Company has not entered into any transactions with any person or entity belonging to the promoter/promoter group which holds 10% or more shareholding in our Company.

DISCLOSURE OF RELATED PARTY TRANSACTIONS WITH SUBSIDIARIES

The Company has invested an amount of Rs. 2,00,000,000/- (Rupees Two Crore) towards subscription to the equity shares of its Wholly owned subsidiary - Vanta Clinical Research Limited. Further, the Company has also entered business transactions with both its subsidiaries- Vanta Clinical Research Limited and Vayam Research Solutions Limited

Details of all related party transactions with Promoters and the subsidiary companies are disclosed in Note 32 of the financial statements.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Issue of equity shares with differential rights as to dividend, voting or otherwise.
2. Issue of shares (including sweat equity shares) to employees of the Company under any scheme.
3. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future.
4. No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and date of report.
5. No change in the nature of business of the Company.

The Company has complied with all the provisions of the secretarial standards as applicable to the Company.

The Company being listed on SME Exchange. Para C, D and E of Schedule V of SEBI (LODR) Regulations, 2015 in connection with disclosures in the annual report are not applicable to the Company.

INSIDER TRADING REGULATIONS

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the code of conduct for prevention of insider trading and the Code for Corporate Disclosures ("Code"), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of shareholders at large, to prevent misuse of any price sensitive information and to prevent any insider trading activity by dealing in shares of the Company by its Directors, designated employees and other employees.

The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, designated employees and other employees from trading in the securities of Vanta Bioscience Limited at the time when there is unpublished price sensitive information.

POLICY ON PRESERVATION OF THE DOCUMENTS

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents to ensure safe keeping of the records and safeguard the Documents from getting manhandled, while at the same time avoiding superfluous inventory of Documents.

OBLIGATION OF THE COMPANY UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

In order to prevent Sexual Harassment of Women at Workplace a new act "The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013" has been notified on 9th December, 2013. Under the said Act every Company is required to set up an Internal Complaints Committee to look into complaints relating to sexual harassment at work place of any women employee. The Company has adopted "Anti-Sexual Harassment Policy" constituted "Redressal Committee" as required under section 4 (1) of Sexual harassment of Women at work place (Prevention, Prohibition and Redressal) Act, 2013.

During the year under review, there were no cases filed/registered pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

ACKNOWLEDGEMENT

Your Directors place on record their appreciation of the continued patronage extended to the Company by bankers, dealers, customers, suppliers, employees and shareholders. The trust reposed in your Company by its esteemed customers helped stabilized growth during the year review.

Your Company also acknowledges the support and guidance received from its Bankers, other government agencies during the year under review and look forward to continuing support.

For and on behalf of the Board

Sd/-

Dopesh RajaMulkala
Managing Director
DIN: 01176660

Sd/-

Sadhanala Venkata Rao
CEO & Whole Time Director
DIN: 02906370

August 27, 2019
 Secunderabad.

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures**Part "A": Subsidiaries**

(Information in respect of each subsidiary to be presented with amounts in Rs.)

Sl. No.	Particulars	Details	
		1	2
1.	Sl. No.		
2.	Name of the subsidiary	Vanta Clinical Research Limited	Vayam Research Solutions Limited
3.	The date since when subsidiary was acquired	September 12, 2018	October 10, 2018
4.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	September 12, 2018 to March 31, 2019	October 10, 2018 to March 31, 2019
5.	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	INR	INR
6.	Share capital	2,00,00,000	2,00,00,000
7.	Reserves & surplus	12,731	28,398
8.	Total assets	2,03,67,503	3,02,49,823
9.	Total Liabilities	2,03,67,503	3,02,49,823
10.	Investments	1,02,00,000	-
11.	Turnover	3,50,000	4,50,000
12.	Profit before taxation	17,204	38,376
13.	Provision for taxation	4,473	9,978
14.	Profit after taxation	12,731	28,398
15.	Proposed Dividend	-	-
16.	Extent of shareholding (In percentage)	100.00%	51*%

**Vanta Clinical Research Limited (WOS of Vanta Bioscience Limited) holds 51% in Vayam Research Solutions Limited. Accordingly, Vayam Research Solutions Limited is a step down subsidiary of Vanta Bioscience Limited*

Notes: The following information shall be furnished at the end of the statement

- Names of subsidiaries which are yet to commence operations: **NA**
- Names of subsidiaries which have been liquidated or sold during the year: **NA**

Part "B": Associates and Joint Ventures – Not Applicable as there are no associates and joint ventures

1. Names of associates or joint ventures which are yet to commence operations: **NA**
2. Names of associates or joint ventures which have been liquidated or sold during the year: **NA**

for **Mathesh & Ramana**
Chartered Accountants

Sd/-
(M. Dopesha Raja)
Managing Director
DIN: 01176660

Sd/-
(S. Venkat Rao)
Whole Time Director and CEO
DIN: 02906370

Sd/-
B. V. Ramana Reddy
M. No. 026967
Partner

Sd/-
(A. Kiran Kumar)
CFO

Sd/-
(Zoheb S Sayani)
Company Secretary
M. No. A32277

Secunderabad
27.08.2019

SECRETARIAL AUDIT REPORTFOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2019

(Pursuant to Section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To**The Members****VANTA BIOSCIENCE LIMITED**

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Vanta Bioscience Limited bearing CIN: L74999TG2016PLC109280 (hereinafter called the “Company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on my verification of the Company’s books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit and as per the explanations given to me and the representations made by the Management, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on March 31, 2019 generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

I have examined the books, papers, minute books, forms and returns filed and other records made available to me and maintained by the Company for the financial year ended on March 31, 2019 according to the applicable provisions of:

- i. The Companies Act, 1956 and the Companies Act, 2013 (‘the Act’) and the rules made there under;
- ii. The Securities Contract (Regulation) Act, 1956 (‘SCRA’) and the rules made there under;
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- iv. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (‘SEBI Act’):
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
 - d. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
 - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not Applicable during the audit period)
 - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act, 2013 and dealings with client;

- g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; (Not Applicable during the audit period)
- h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; (Not Applicable during the audit period) and
- i. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and amendments thereof
- vi. Other Laws specifically applicable to the Company:
 - a. Pharmacy Act, 1948
 - b. Bio-Medical Waste (Management and Handling) Rules, 1998
 - c. Legal Metrology Act, 2009;
 - d. Prevention of Cruelty to Animals Act, 1960 and the Breeding of and Experiments on Animals (Control and Supervision) Rules, 1998
 - e. Guidelines for care and use of animals in scientific research
 - f. Good Laboratory Practices
 - g. Water (Prevention and Control of Pollution) Act, 1974
 - h. Water (Prevention and Control of Pollution) Cess Act, 1977
 - i. Air (Prevention and Control of Pollution) Act, 1981
 - j. Environment (Protection) Act, 1986
 - k. The Public Liability Insurance Act, 1991
 - l. The Biodiversity Act, 2002
 - m. Hazardous Wastes (Management and Handling) Rules, 1989
 - n. Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008
 - o. Manufacture, Storage and Import of Hazardous Chemicals Rules, 1989;
 - p. Explosives Act, 1884.
 - q. Explosives Rules, 2008.

I have also examined compliance with the Secretarial Standards issued by the Institute of Company Secretaries of India and the Listing Regulations as applicable to the Company.

The compliance of the above laws is based on the Compliance Certificate issued by the CEO and Whole Time Director of the Company and submitted to the Board of Directors of the Company. During the Audit Period under review and as per the explanation and clarifications given to me and the representations made by the Management, the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, etc. mentioned above *except that there were certain discrepancies/lapses in compliance with erstwhile Regulation 72(2) and certain other provisions of erstwhile Chapter VII SEBI (ICDR) Regulations, 2009 in connection with preferential issue. (currently Chapter V of SEBI (ICDR) Regulations, 2018)*

I further report that, during the year under review:

- a) The Company had filed certain forms after the due date by payment of additional fee.
- b) The compliance by the Company of applicable financial laws, like direct and indirect tax laws, have not been reviewed in this Audit since the same has been subject to review by statutory financial audit and other designated professionals;

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non - Executive Directors and Independent Directors. The composition of the Board of Directors are in compliance with the provisions of the Act.

Adequate notice was given to all Directors at least seven days in advance to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting. Whenever required, the Board has also met with a notice shorter than seven days.

Decisions at the Board Meetings, as represented by the management, were taken by majority and recorded as part of the minutes.

As per the explanations given to me and the representations made by the Management and relied upon by me, I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that:

- The shareholders of the Company in their EGM held on September 29, 2018 have approved issue and allotment of 13,74,000 equity shares of Rs. 10/- each at a premium of Rs. 75/- to Promoters and Non Promoters. Subsequently, the Board in its meeting held on November 28, 2018 have approved allotment of 5,84,000 equity shares of Rs.10/- at a premium of Rs. 75/- each. The Company made necessary applications to BSE Ltd, NSDL and CDSL. Accordingly, BSE Ltd has granted its trading approval for said number of shares vide their Notice No.20190128-10 dated January 28, 2019 and were permitted to trade with effect from January 29, 2019.
- The Company has incorporated one wholly owned subsidiary in the name of Vanta Clinical Research Limited and one 51% step down subsidiary in the name of Vayam Research Solutions Limited.

for Tapasvilal Deora & Associates

Practising Company Secretaries

Sd/-

Tapasvilal Deora

M. No.: F9813

C.P. No.: 13087

August 27, 2019

Hyderabad

This Report is to be read with my letter of even date which is annexed as Annexure A and forms an integral part of this report.

Encl:

Annexure A

To

The Members

VANTA BIOSCIENCE LIMITED

My report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the process and practices, I followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, I have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

for Tapasvilal Deora & Associates

Practising Company Secretaries

Sd/-

Tapasvilal Deora

M. No.: F9813

C.P. No.: 13087

August 27, 2019

Hyderabad

Remuneration Policy for Directors, Keymanagerial Personnel and Other Employees**1. INTRODUCTION:**

1.1 **VANTA BIOSCIENCE LIMITED** (“VBS”) recognizes the importance of aligning the business objectives with specific and measureable individual objectives and targets. The Company has therefore formulated the remuneration policy for its directors, key managerial personnel and other employees keeping in view the following objectives:

- 1.1.1 Ensuring that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate, to run the company successfully.
- 1.1.2 Ensuring that relationship of remuneration to performance is clear and meets the performance benchmarks.
- 1.1.3 Ensuring that remuneration involves a balance between fixed and incentives pay reflecting short and long term performance objectives appropriate to the working of the company and its goals.

2. SCOPE AND EXCLUSION:

2.1 This Policy sets out the guiding principles for the Nomination and Remuneration Committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the Company.

3. TERMS AND REFERENCES:

In this Policy, the following terms shall have the following meanings:

3.1 “**Director**” means a director appointed to the Board of a Company.

3.2 “**Key Managerial Personnel**” means

- i. the Chief Executive Officer or the managing director or the manager;
- ii. the company secretary;
- iii. the whole-time director;
- iv. the Chief Financial Officer; and
- v. such other officer as may be prescribed under the Companies Act, 2013

3.3 “**Nomination and Remuneration Committee**” means the committee constituted by VBS’s Board in accordance with the applicable provisions of the Companies Act, 2013 and the Listing Regulations.

4. POLICY:

4.1 Remuneration to Executive Directors and Key Managerial Personnel

- 4.1.1 The Board, on the recommendation of the Nomination and Remuneration (NAR) Committee, shall review and approve the remuneration payable to the Executive Directors of the Company within the overall limits approved by the shareholders.
- 4.1.2 The Board, on the recommendation of the Committee, shall also review and approve the remuneration payable to the Key Managerial Personnel of the Company.
- 4.1.3 The Annual Plan and Objectives for Executive Directors and Senior Executives (Management Committee) shall be reviewed by the Committee as the case may be and Annual Performance Bonus will be approved by the Committee based on the achievements against the Annual Plan and Objectives as may be decided by the Committee.

4.2 Remuneration to Non-Executive Directors

- 4.2.1 The Board, on the recommendation of the Committee, shall review and approve the remuneration payable to the Non-Executive Directors of the Company within the overall limits approved by the shareholders and in accordance with the provisions of the Companies Act and Listing Regulations.
- 4.2.2 Non-Executive Directors shall be entitled to sitting fees for attending the meetings of the Board and the Committees thereof.

4.3 Remuneration to other employees

- 4.3.1 Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile, skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

5. Secretary

The Company Secretary of the Company shall act as Secretary of the NR Committee.

**STATEMENT PURSUANT TO SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH RULE 8 OF
THE COMPANIES (ACCOUNTS) RULES, 2014**

(A) Conservation of energy-

- (i) the steps taken or impact on conservation of energy: Nil
- (ii) the steps taken by the company for utilizing alternate sources of energy: Nil
- (iii) the capital investment on energy conservation equipments: Nil

(B) Technology absorption-

- (i) the efforts made towards technology absorption: Nil
- (ii) the benefits derived like product improvement, cost reduction, product development or import substitution: Nil
- (iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-
 - (a) the details of technology imported: Nil
 - (b) the year of import: Nil
 - (c) whether the technology been fully absorbed: Nil
 - (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof: Nil
- (iv) the expenditure incurred on Research and Development: Rs. 4,86,22,591/-

(C) Foreign exchange earnings and Outgo-

The Foreign Exchange earned in terms of actual inflows during the year : Rs 3,76,11,936/-

The Foreign Exchange outgo during the year in terms of actual outflows:

S. No.	Particulars	Amount (Rs.)
1	Value of Imports	1,26,96,698
2	Expenditure in foreign currency	14,17,008
	Total	1,41,13,706

During the year, there was a foreign exchange loss of Rs. 2,28,347/- to the Company.

For and on behalf of the Board

Sd/-

Dopesh RajaMulakala
Managing Director
DIN: 01176660

Sd/-

Sadhanala Venkata Rao
CEO & Whole Time Director
DIN: 02906370

August 27, 2019

Secunderabad

FORM NO. MGT 9

EXTRACT OF ANNUAL RETURN

as on the financial year ended on 31-03-2019

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

CIN	L74999TG2016PLC109280
Registration Date	April 29, 2016
Name of the Company	VANTA BIOSCIENCE LIMITED (formerly known as Vanta Bioscience Private Limited)
Category/Sub-Category of the Company	Company limited by Shares/ Indian Non-Government Company
Address of the Registered office and contact details	No.02/G/308/G No.3/FF/SF/1-20-248 Umajay Complex, Rasoolpura, Secunderabad – 500003, Telangana Contact: 040 66575454 Email id: cs@vantabio.com
Whether listed company	Yes – listed on SME platform of BSE Ltd. w.e.f Oct 06, 2017
Name, Address and Contact details of Registrar and Transfer Agent, if any	Bigshare Services Private Limited 306, Right Wing, Amrutha Ville Apts. Somajiguda, Hyderabad – 500 082 Contact No. : 040 2337 4967 E-Mail : prabhakar@bigshareonline.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Business activities contributing 10 % or more of the total turnover of the company

S.No	Name and Description of main products/ services	NIC Code of the Product/ service	% to total turnover of the company
1	Preclinical Activities and other CRO Activities (Scientific research and development)	72	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES

S.No	Name and Address of The company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1	Vanta Clinical Research Limited No.02/G/308/G, No.3/FF/SF/1-20-248, Umajay Complex, Rasoolpura Secunderabad Hyderabad Telangana 500003	U73100TG2018PLC126673	Subsidiary	100	2 (87) (ii)
2	Vayam Research Solutions Limited No.02/G/308/G, No.3/FF/SF/1-20-248, Umajay Complex, Rasoolpura Secunderabad Hyderabad Telangana 500003	U73100TG2018PLC127550	Step Down Subsidiary*	51%	2 (87) (ii)

*Vanta Clinical Research Limited, which is our Wholly Owned Subsidiary holds 51% in Vayam Research Solutions Limited. Accordingly, Vayam Research Solutions Limited is our Step down subsidiary.

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year [As on 01-April-2018]				No. of Shares held at the end of the year [As on 31-March-2019]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoter and Promoter Group									
(1) Indian									
a) Individual/ HUF	41,50,000	-	41,50,000	72.45	44,14,000	-	44,14,000	69.93	(2.52)
b) Central Govt	-	-	-	-	-	-	-	-	-
c) State Govt(s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp.	-	-	-	-	-	-	-	-	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any other	-	-	-	-	-	-	-	-	-
Sub Total (A) (1)	41,50,000	-	41,50,000	72.45	44,14,000	-	44,14,000	69.93	(2.52)
(2) Foreign									
a) NRI Individuals	-	-	-	-	-	-	-	-	-
b) Other Individuals	-	-	-	-	-	-	-	-	-
c) Bodies Corp.	-	-	-	-	-	-	-	-	-
d) Banks / FI	-	-	-	-	-	-	-	-	-
e) Any other	-	-	-	-	-	-	-	-	-
Sub Total (A) (2)	-	-	-	-	-	-	-	-	-
Total (A)	41,50,000	-	41,50,000	72.45	44,14,000	-	44,14,000	69.93	(2.52)
B. Public Shareholding									
1. Institutions									
a) Mutual Funds	-	-	-	-	-	-	-	-	-
b) Banks / FI	-	-	-	-	-	-	-	-	-
c) Central Govt	-	-	-	-	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	-	-	-	-	-	-	-	-	-
g) FIIs	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
Sub-total (B)(1):-	-	-	-	-	-	-	-	-	-
2. Non-Institutions									
a) Bodies Corp.	-	-	-	-	-	-	-	-	-
i) Indian	1,35,000	-	1,35,000	2.36	67,500	-	67,500	1.07	(1.29)
ii) Overseas	-	-	-	-	-	-	-	-	-

b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	8,42,821	20,000	8,62,821	15.06	7,18,872	-	7,18,872	11.39	(3.67)
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	5,45,000	-	5,45,000	9.51	10,38,500	-	10,38,500	16.45	6.94
c) Others (specify)	-	-	-	-	-	-	-	-	-
Non Resident Indians	18,000	-	18,000	0.31	12,000	-	12,000	0.19	(0.12)
Overseas Corporate Bodies	-	-	-	-	-	-	-	-	-
Foreign Nationals	-	-	-	-	-	-	-	-	-
Clearing Members	17,179	-	17,179	0.30	61,128	-	61,128	0.97	0.67
Trusts	-	-	-	-	-	-	-	-	-
Foreign Bodies - D R	-	-	-	-	-	-	-	-	-
HUF	-	-	-	-	-	-	-	-	-
Sub-total (B)(2):-	1,35,000	-	1,35,000	2.36	18,98,000	-	18,98,000	30.07	2.52
Total Public (B)	1,35,000	-	1,35,000	2.36	18,98,000	-	18,98,000	30.07	2.52
C. Shares held by Custodian for GDRs & ADRs	-	-	-	-	-	-	-	-	-
Grand Total (A+B+C)	57,08,000	20,000	57,28,000	100	63,12,000	0	63,12,000	100	0

(ii) Shareholding of Promoters

S.No	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1)	Mohan Krishna Mulakala							
	At the beginning of the year	34,85,500	60.85	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	34,85,500	55.22	-	-5.63*
2)	Dopesh Raja Mulakala							
	At the beginning of the year	1,94,000	3.39	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year (Allotment of 2,64,000 equity shares under Preferential Issue - November 28, 2018)	2,64,000	4.18	-	4,58,000	7.26	-	-
	At the End of the year	-	-	-	4,58,000	7.26	-	3.87*

S.No	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
3)	Mulakala Sujana Sheela							
	At the beginning of the year	100	0.00	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	100	0.00	-	-
4)	Simhadri Soumya							
	At the beginning of the year	90,100	1.57	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	90,100	1.42	-	-0.15*
5)	Mulakala Karishma							
	At the beginning of the year	50,100	0.87	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	50,100	0.80	-	-0.08*
6)	Chintapatla Shravan							
	At the beginning of the year	80,100		1.40	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	80,100	1.27	-	-0.13*
7)	Mulakala Sajan Kiran							
	At the beginning of the year	20,100	0.35	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	20,100	0.32	-	-0.03*
8)	Pradeep Chowdhary V							
	At the beginning of the year	80,000	1.40	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	80,000	1.27	-	-0.13*
9)	Vyas Madhavrao Shingatgeri							
	At the beginning of the year	50,000	0.87	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	50,000	0.80	-	-0.08*
10)	Chandra Sekhar Rao Simhadri							
	At the beginning of the year	1,00,000	1.75	-	-	-	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	At the End of the year	-	-	-	1,00,000	1.58	-	-0.16*
	TOTAL	41,50,000	72.45	-	44,14,000	69.93	-	(2.52)

*Decrease in percentage due to allotment of equity shares to Promoters and non-promoters on preferential basis on November 28, 2018.

(iii) Change in Promoters' Shareholding:

S.No		Shareholding at the beginning of the year		Cumulative Share holding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	At the beginning of the year	41,50,000	72.45	41,50,000	72.45
	Changes				
	• Allotment under Preferential Issue – November 28, 2018	2,64,000	4.18	44,14,000	69.93
	At the End of the year	44,14,000	69.93	44,14,000	69.93*

**Decrease in percentage due to allotment of 3,20,000 equity shares to non-promoters on preferential basis on November 28, 2018.*

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs): Annexure

Sr.No.	NAME	No. of Shares at the beginning/End of the year	Date	Increase/Decrease in share holding	Reason	Number of Shares	Percentage of total shares of the company
1	HRIDAAN CHOPRAA	0	31-Mar-18		Transfer	0	0.00
			20-Jul-18	30000	Transfer	30,000	0.48
			3-Aug-18	57000	Transfer	87,000	1.38
			24-Sep-18	-87000	Transfer	0	0.00
			28-Sep-18	87000	Transfer	87,000	1.38
			30-Mar-19	0	Transfer	87,000	1.38
2	INVENTURE GROWTH & SECURITIES LTD.	87,000	31-Mar-18	0	Transfer	87,000	1.38
			6-Apr-18	-3000	Transfer	84,000	1.33
			13-Apr-18	3000	Transfer	87,000	1.38
			20-Apr-18	3000	Transfer	90,000	1.43
			27-Apr-18	3000	Transfer	93,000	1.47
			11-May-18	6000	Transfer	99,000	1.57
			18-May-18	-3000	Transfer	96,000	1.52
			25-May-18	-6000	Transfer	90,000	1.43
			1-Jun-18	3000	Transfer	93,000	1.47
			8-Jun-18	9000	Transfer	1,02,000	1.62
			15-Jun-18	-6000	Transfer	96,000	1.52
			22-Jun-18	3000	Transfer	99,000	1.57
			29-Jun-18	-99000	Transfer	0	0.00
			30-Mar-19	0	Transfer	0	0.00

VANTA BIOSCIENCE LIMITED

Sr.No.	NAME	No. of Shares at the begining/End of the year	Date	Increase/ Decrease in share -holding	Reason	Number of Shares	Percentage of total shares of the company
3	M REKHA	84,000	31-Mar-18	0	Transfer	84,000	1.33
			15-Jun-18	3000	Transfer	87,000	1.38
			20-Jul-18	-30000	Transfer	57,000	0.90
			3-Aug-18	-57000	Transfer	0	0.00
			30-Mar-19	0	Transfer	0	0.00
4	RUDRA MURTHY VIBHUSHANKAR BANGALORE	0	31-Mar-18		Transfer	0	0.00
			29-Jun-18	19700	Transfer	19,700	0.31
			6-Jul-18	31450	Transfer	51,150	0.81
			13-Jul-18	14850	Transfer	66,000	1.05
			27-Jul-18	-3000	Transfer	63,000	1.00
			21-Aug-18	3000	Transfer	66,000	1.05
			24-Sep-18	-66000	Transfer	0	0.00
			28-Sep-18	66000	Transfer	66,000	1.05
		66,000	30-Mar-19	0	Transfer	66,000	1.05
5	SS SEEMA	33,000	31-Mar-18	0	Transfer	33,000	0.52
			24-Sep-18	-33000	Transfer	0	0.00
			28-Sep-18	33000	Transfer	33,000	0.52
			1-Feb-19	1500	Transfer	34,500	0.55
			8-Feb-19	30000	Transfer	64,500	1.02
			15-Feb-19	1500	Transfer	66,000	1.05
			29-Mar-19	-3000	Transfer	63,000	1.00
		63,000	30-Mar-19	0	Transfer	63,000	1.00
6	KIRANMAYI K .	60,000	31-Mar-18	0	Transfer	60,000	0.95
			24-Sep-18	-60000	Transfer	0	0.00
			28-Sep-18	60000	Transfer	60,000	0.95
		60,000	30-Mar-19	0	Transfer	60,000	0.95
7	F L DADABHOY	24,000	31-Mar-18	0	Transfer	24,000	0.38
			7-Sep-18	6000	Transfer	30,000	0.48
			24-Sep-18	-30000	Transfer	0	0.00
			28-Sep-18	30000	Transfer	30,000	0.48
			8-Feb-19	24000	Transfer	54,000	0.86
		54,000	30-Mar-19	0	Transfer	54,000	0.86
8	VINOD KUMAR SHARMA	0	31-Mar-18		Transfer	0	0.00
			13-Jul-18	3000	Transfer	3,000	0.05
			27-Jul-18	12000	Transfer	15,000	0.24
			7-Sep-18	9000	Transfer	24,000	0.38
			14-Sep-18	9000	Transfer	33,000	0.52
			24-Sep-18	-33000	Transfer	0	0.00
			28-Sep-18	33000	Transfer	33,000	0.52
			29-Mar-19	6000	Transfer	39,000	0.62
		39,000	30-Mar-19	0	Transfer	39,000	0.62

VANTA BIOSCIENCE LIMITED

Sr.No.	NAME	No. of Shares at the begining/End of the year	Date	Increase/Decrease in share -holding	Reason	Number of Shares	Percentage of total shares of the company
9	RAJKUMARI VIMALCHAND.	18,000	31-Mar-18	0	Transfer	18,000	0.29
			8-Jun-18	-3000	Transfer	15,000	0.24
			29-Jun-18	15000	Transfer	30,000	0.48
			6-Jul-18	-6000	Transfer	24,000	0.38
			13-Jul-18	3000	Transfer	27,000	0.43
			27-Jul-18	6000	Transfer	33,000	0.52
			3-Aug-18	3000	Transfer	36,000	0.57
			21-Aug-18	3000	Transfer	39,000	0.62
			7-Sep-18	-3000	Transfer	36,000	0.57
			24-Sep-18	-36000	Transfer	0	0.00
			28-Sep-18	45000	Transfer	45,000	0.71
			5-Oct-18	3000	Transfer	48,000	0.76
			12-Oct-18	-3000	Transfer	45,000	0.71
			2-Nov-18	-3000	Transfer	42,000	0.67
			9-Nov-18	1500	Transfer	43,500	0.69
			16-Nov-18	3000	Transfer	46,500	0.74
			23-Nov-18	-1500	Transfer	45,000	0.71
			30-Nov-18	-1500	Transfer	43,500	0.69
			14-Dec-18	1500	Transfer	45,000	0.71
			18-Jan-19	750	Transfer	45,750	0.72
			25-Jan-19	750	Transfer	46,500	0.74
			1-Feb-19	-4500	Transfer	42,000	0.67
			8-Feb-19	-3000	Transfer	39,000	0.62
			1-Mar-19	1500	Transfer	40,500	0.64
			8-Mar-19	-1500	Transfer	39,000	0.62
		39,000	30-Mar-19	0	Transfer	39,000	0.62
10	A.VIMAL CHAND	18,000	31-Mar-18	0	Transfer	18,000	0.29
			29-Jun-18	3000	Transfer	21,000	0.33
			6-Jul-18	-3000	Transfer	18,000	0.29
			13-Jul-18	3000	Transfer	21,000	0.33
			24-Aug-18	3000	Transfer	24,000	0.38
			31-Aug-18	-3000	Transfer	21,000	0.33
			24-Sep-18	-21000	Transfer	0	0.00
			28-Sep-18	15000	Transfer	15,000	0.24
			5-Oct-18	-3000	Transfer	12,000	0.19
			12-Oct-18	3000	Transfer	15,000	0.24
			2-Nov-18	-3000	Transfer	12,000	0.19

VANTA BIOSCIENCE LIMITED

Sr.No.	NAME	No. of Shares at the beginning/End of the year	Date	Increase/Decrease in share holding	Reason	Number of Shares	Percentage of total shares of the company
			9-Nov-18	9000	Transfer	21,000	0.33
			16-Nov-18	-1500	Transfer	19,500	0.31
			30-Nov-18	6000	Transfer	25,500	0.40
			28-Dec-18	1500	Transfer	27,000	0.43
			1-Feb-19	3000	Transfer	30,000	0.48
			8-Feb-19	2979	Transfer	32,979	0.52
			15-Feb-19	521	Transfer	33,500	0.53
			22-Feb-19	-500	Transfer	33,000	0.52
			8-Mar-19	1500	Transfer	34,500	0.55
			15-Mar-19	3000	Transfer	37,500	0.59
		37,500	30-Mar-19	0	Transfer	37,500	0.59

(v) Shareholding of Directors and Key Managerial Personnel:

S. No	For each of the Directors and KMP	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the company	No. of Shares	% of total Shares of the company
1	Mohan Krishna Mulakala				
	At the beginning of the year	34,85,500	60.85	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	34,85,500	55.22*
2	Dopesh Raja Mulakala				
	At the beginning of the year	1,94,000	3.39	-	-
	Date wise Increase/Decrease in Shareholding during the year (Allotment of 2,64,000 equity shares under Preferential Issue - November 28, 2018)	2,64,000	4.18	4,58,000	7.26
	At the End of the year	-	-	4,58,000	7.26
3	Padmanabhuni Venkata Appaji				
	At the beginning of the year	Nil	Nil	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	Nil	Nil
4	Sadhanala Venkata Rao				
	At the beginning of the year	Nil	Nil	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	Nil	Nil

S. No	For each of the Directors and KMP	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of total Shares of the company	No. of Shares	% of total Shares of the company
5	Vyasmurti Madhavrao Shingatgeri				
	At the beginning of the year	50,000	0.87	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	50,000	0.80*
6	Jang Bahadur Gupta				
	At the beginning of the year	Nil	Nil	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	Nil	Nil
7	Gonuguntla Kathyayani				
	At the beginning of the year	Nil	Nil	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	Nil	Nil
8	Zoheb Sultan Ali Sayani				
	At the beginning of the year	Nil	Nil	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	Nil	Nil
9	Kiran Kumar Annabatula				
	At the beginning of the year	Nil	Nil	-	-
	Date wise Increase/Decrease in Shareholding during the year	Nil	Nil	Nil	Nil
	At the End of the year	-	-	Nil	Nil

*No change in shareholding - Decrease in percentage is due to allotment of 5,84,000 equity shares on preferential basis on November 28, 2018.

V. INDEBTEDNESS**Indebtedness of the Company including interest outstanding/accrued but not due for payment****Amount in INR**

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	10,68,00,532	-	-	10,68,00,532
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	10,59,133	-	-	10,59,133
Total (i + ii + iii)	10,78,59,665	-	-	10,78,59,665
Change in Indebtedness during the financial year				
• Addition	2,56,62,242	-	-	2,56,62,242
• Reduction	-	-	-	-
Net Change	2,56,62,242	-	-	2,56,62,242
Indebtedness at the end of the financial year				
i) Principal Amount	13,24,62,774	-	-	13,24,62,774
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	14,48,695	-	-	14,48,695
Total (i + ii + iii)	13,39,11,469	-	-	13,39,11,469

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL**A. Remuneration to Managing Director, Whole-time Directors and/or Manager: Amount in INR**

S.No	Particulars of Remuneration	Dopesh Raja Mulakala (MD)	Dr. Vyasmurthi Madhava Rao (WTD)	Venkata Rao Sadhanala (CEO & WTD)#	Total Amount
1.	Gross salary	30,00,000	31,89,579	60,00,000	1,21,89,579
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961				
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961				
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-
2.	Stock Option	-	-	-	-
3.	Sweat Equity	-	-	-	-
4.	Commission				
	- as % of profit				
	- others, specify...	-	-	-	-
5.	Others, please specify	-	-	-	-
	Total (A)	30,00,000	31,89,579	60,00,000	1,21,89,579
	Ceiling as per the Act	30,00,000*	60,00,000*	60,00,000*	1,50,00,000*

*As approved by the shareholders in EGM

#Appointed as CEO & WTD w.e.f 05.01.2018 and approved by shareholders in their EGM on 07.02.2018

B. Remuneration to other directors:**(Amount in Rs.)**

S.No	Particulars of Remuneration	Name of Directors			Total Amount
		Dr. J.B. Gupta	Dr. P.V Appaji	Dr. G. Kathyayani	
1.	Independent Directors*				
	• Fee for attending board / committee Meetings	-	1,30,000	1,02,500	2,32,500
	• Commission	-	-	-	-
	• Others, please specify	-	-	-	-
	Total (1)	-	1,30,000	1,02,500	2,32,500
2.	Other Non-Executive Directors				
	• Fee for attending board / committee meetings	-	-	-	-
	• Commission	-	-	-	-
	• Others, please specify (Salary)	-	-	-	-
	Total (2)	-	-	-	-
	Total (B)=(1+2)	-	1,30,000	1,02,500	2,32,500
	Total Managerial Remuneration	-	-	-	-
	Overall Ceiling as per the Act	-	-	-	-

*Sitting fees paid to Independent Directors are within the limits prescribed under the Act.

C. Remuneration to KMP Other Than MD/Manager/WTD**(Amount in Rs.)**

S.No	Particulars of Remuneration	KMP		Total Amount
		CS Zoheb Sayani	CFO Kiran Kumar Annabatula	
1.	Gross salary	2,40,000	-	2,40,000
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-
2.	Stock Option	-	-	-
3.	Sweat Equity	-	-	-
4.	Commission- as % of profit- others, specify...	-	-	-
5.	Others, please specify	-	-	-
	Total (A)	2,40,000	-	2,40,000
	Ceiling as per the Act	NA	NA	NA

VII. PENALTIES / PUNISHMENT / COMPOUNDING OF OFFENCES:

Type	Section of The Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give Details)
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
OTHER OFFICERS IN DEFAULT					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-

For and on behalf of the Board

Sd/-
Dopesh RajaMulakala
Managing Director
DIN: 01176660

Sd/-
Sadhanala Venkata Rao
CEO & Whole Time Director
DIN: 02906370

August 27, 2019
Secunderabad

Annexure VI

Disclosures under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

- i. The ratio of the remuneration of each director to the median remuneration of the employees of the company -

S.No.	Name of Director	Remuneration	Median Employee Salary	Ratio
1	Mr. Mulakala Dopesha Raja	30,00,000	2,21,599	13.5:1
2	Mr. Mulakala Mohan Krishna	NIL	2,21,599	NIL
3	Dr. Padmanabhuni Venkata Appaji	NIL	2,21,599	NIL
4	Mr. Sadhanala Venkata Rao	60,00,000	2,21,599	14.9:1
5	Dr. Vyasmurti Madhavrao Shingatgeri	31,89,579	2,21,599	14.4:1
6	Dr. Jang Bahadur Gupta	NIL	2,21,599	NIL
7	Dr. Gonuguntla Kathyayani	NIL	2,21,599	NIL

- ii. The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive officer, Company Secretary or manager, if any, in the Financial Year:
There was no percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer and Company Secretary during the Financial Year.
Details of appointments, change in designation & remuneration of all the Directors are mentioned in the Board's Report and MGT-9.
- iii. The percentage increase in the median remuneration of the employees in the financial year: Nil
- iv. There were 53 Permanent employees on the rolls of the Company, as on March 31, 2019.
- v. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration;
Average percentile increase for Non Managerial Personnel was 9.08% during the last Financial Year.
There was no percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer and Company Secretary during the Financial Year.
Details of appointments, change in designation & remuneration of all the Directors are mentioned in the Board's Report and MGT-9.
- vi. The key parameters of any variable component of remuneration availed by the directors;
50% of total salary is variable component which will be paid after successful completion of the KRA's fixed by the company for Mr. Sadhanala Venkata Rao, CEO & WTD.
- vii. Affirmation that the remuneration is as per the remuneration policy of the Company.
The remuneration paid to Directors is as per the remuneration policy of the Company.

viii. Top 10 Employees in terms of remuneration:

Name	Age	Qualification	Designation	Date of commencement employment	Experience Gross (years)	Nature of employment	Remuneration Per Month	No of equity shares	Previous Employment	Relative Director if any of
VYAS MADHAVRAO SHINGATGERI	57	PHD (Veterinary-Animal Biotechnology)	Whole Time Director	01-04-2017	18	Permanent	2,65,798	50,000	Sun Pharma	No
DOPESH RAJA MULAKALA	33	MBA, PGDMA	Managing Director	01-04-2017	11	Permanent	2,50,000	4,58,000	Sarvotham Care Limited	Yes
VENKAT RAO SADHANALA	55	CA,CS,LLB	CEO&Whole Time Director	02-05-2017	29	Permanent	5,00,000	-	ICOM Ltd	No
DEEPAK SHARMA	51	MVSc (Veterinary-Animal Biotechnology)	Dy. TFM	01-04-2017	22	Permanent	2,18,710	-	Sun Pharma	No
DR.JAIPRAKASH JAYSINGRAO B	43	MVSC	Assistant Director	01-04-2017	17	Permanent	1,65,209	-	Sun Pharma	No
SATHYA TN	37	Ph.D (Biotechnology-Toxicology), DABT (Toxicology)	Principle Scientist	01-04-2017	13	Permanent	88,199	-	IIBAT	No
SANJAYA R J	59	M.Sc. Zoology	GM	30-05-2018	22	Permanent	87,470	-	Bio Needs India Private Ltd	No
NAMRATA SINGH	37	Msc Microbiology	Sr. Manager(BDM)	15-05-2017	13	Permanent	76,554	N	Bio Needs India Private Ltd	No
B S HARISHCHANDRA	37	BSC Computers	Manager	16-02-2018	14	Permanent	73,861	N	Tanga Pharmaceuticals and Cosmetics	No
NAGAMA NAIDU M	36	M.Sc. Microbiology	Senior Research Scientist	02-04-2018	11	Permanent	67,522	N	RCC Laboratories	No

MANAGEMENT DISCUSSION AND ANALYSIS REPORT**MANAGEMENT DISCUSSION AND ANALYSIS**

The Management Discussion and Analysis given below covers the key issues concerning the business carried on by the Company with respect to Industry Overview, Outlook, Trends, Opportunities, Threats & Risks.

Industry Structure and Developments:**An Overview of the company**

Vanta Bioscience Limited ("Vanta or Company") is an emerging, full service preclinical contract research organization, operating out of Chennai, India. Vanta is established as a center of excellence for GLP toxicology and safety assessment.

Industrial Overview

Indian economy is one of the largest and fastest growing economies in the world. The Food & Agri industry is among the top three sectors in India that propel the Indian economy, which is predicted to experience further robust growth in the coming years. The pharmaceutical industry too is one of the primary economic drivers in India which currently is facing headwinds due to increased regulatory scrutiny and a slowdown in the US and a few other leading pharmaceutical markets globally. However undeterred, the Indian pharmaceutical industry shows a trend of increased spending on outsourcing compliance related testing needs and also an increased R&D spending to develop new drugs. Whether it be the increasing focus on food safety and quality in the country, driven by FSSAI and quality conscious manufacturers and customers, or the regulatory challenges being faced by the Indian pharmaceutical industry, these trends create huge opportunities for food and pharmaceuticals testing and research services (both routine and sophisticated). Like in any business, these opportunities come along with challenges such as increased competition from more local and global players and insufficient number of skilled and trained human resources. Added to this is the unlevel playing field amongst the competition in terms of quality of services and the perceived value of the same by the customers. Healthcare spending is globally high, more now than ever, due to an increasing demand for more and newer medicines in emerging economies. Globally, the pharmaceutical industry continues to be under pressure to get more out of every dollar spent on new product development, and reduce the time between the concept to the product. Given the slow and low returns on investments, the companies look to focus more and more on specialty healthcare segments and products. Therefore, there is an increased demand for cost effective and quick R&D and manufacturing processes. Although India doesn't currently seem to be among the most preferred destination for outsourcing new R&D activities, the cost efficiencies it can deliver to the global pharmaceutical industry is undeniable.

Outlook:

Our Company's activities are guided by the principles of quality services, safety of its employees and business prudence. The Company would put all its efforts to achieve good results within its ambit. The Company regularly focuses on increasing productivity and efficiency, cutting expenses, innovating services and profitable streams of Business. The Company endeavors to use its resources optimally and work persistently towards its set goals.

Internal Control System and their adequacy:

The Company has a well-defined internal control system that is adequate and commensurate with the size and nature of its business. Internal Audit department is put in place and adequate internal controls are established to ensure that all assets are safeguarded and protected against any loss from unauthorized use or disposition and all the transactions are authorized, recorded and reported correctly. ERP based controls are in place.

Opportunities:
The following are the opportunities:

- Our Company has also entered into exclusive tie ups to expand its business in the pre-clinical services sector in Greater China. The Company has also entered into non-exclusive agreements to cover the markets of Latin America (LATAM) and Asia Pacific (APAC) for Chemical and Agrochemical business.
- Strengthening FSSAI's oversight on food safety and quality.
- Global regulatory bodies' emphasis on GLP, NABL, MHRL etc., compliance.
- Indian Health care sector, one of the fastest growing industry, is expected to advance at a CAGR of 22.87% during 2015-20 to reach \$ 280 billion.
- Indian pharmaceuticals market is estimated to reach around \$30 billion in 2015. The pharmaceutical's industry is expected to expand at a CAGR of 12.89 % over 2015-20 to reach \$ 55 billion.
- The number of ANDA approvals granted by US FDA increased from 109 in FY 15 to 201 in FY 16 to the Indian companies.

Threats:
The following are the threats:

- Facilities are subject to client inspections and quality audits and any failure to meet their expectations or to comply with the quality standards set out in contractual arrangements, could result in the termination of contracts and adversely affects business, results of operations, financial condition and cash flows.
- Significant disruptions of information technology systems or breaches of data security.
- Foreign exchange risks that could adversely affect results of operations.
- Political, economic or other factors that are beyond control may have an adverse effect on business and results of operations.
- Changing laws, rules and regulations and legal uncertainties in India, including adverse application of corporate and tax laws.

Challenges, Risks and Concerns:

Risks are inherent to any business. The opportunities compound challenges and vice versa. Risks are managed by your Company through a risk management process of risk identification, risk mitigation through risk reduction strategies & plans and continuous monitoring of the effectiveness of the risk mitigation measures to control them. Your company continues to strive to stay ahead on the competition curve through creation of new service opportunities, and its uncompromising commitment to quality, regulatory compliance and customer service.

Discussion on Financial Performance with respect to Operational Performance:
Key Performance indicators for the year under review is as follows:

Debtors Turnover	42 DAYS
Inventory Turnover	172 DAYS
Interest Coverage	1.69
Current Ratio	4.41
Debt Equity	0.62
Operating Profit Margin	18%
Net Profit Margin	11%
Return on Net Worth	3.01%

Accounting Treatment and Financial Performance

The financial statements are prepared in compliance to the Accounting Standards as laid down under the provisions of section 133 of the Companies Act, 2013.

The financial statements are prepared in compliance to the Accounting Standards as laid down under the provisions of section 133 of the Companies Act, 2013. Gross revenue for the year 2018-19 is Rs. 1265.37 Lakhs as compared to Gross revenue for the year 2017-18 which was Rs. 403.87 Lakhs and the Net profit for the year 2018-19 stood at Rs.69.38 lakhs as compared to the Net profit for the year 2017-18 which was Rs. 2.73 lakhs.

Segment-wise or Product-wise Performance

The Company is providing services of Testing and Contract Research in the fields of Clinical Research, Pre-Clinical Research, Biopharma services, Analytical Testing & Research and Environmental studies. Since the inherent nature of all these services are inter related and governed by similar set of risks and returns and operating in the same economic environment, segment reporting is not applicable. Accordingly, for reporting purposes, all these services are treated as single business and geographical segment. The said treatment is in accordance with Accounting Standard-17 Segment Reporting.

Human Resources Development and Industrial Relations:

At Vanta, we believe that people embody our most fundamental asset. It is our endeavour to offer a fair, transparent and merit-based working environment, which promotes constant learning, individual and organisational development. Human Resource is one of the key strength of the Company. At the end of the financial year 31.03.2019, the Company had 53 employees including 16 Scientist. The dedication and expertise of our team has helped us chart a steady growth path.

Cautionary Statement:

Statements in this Management Discussion and Analysis describing the Company's objective, projections, estimates and expectations may be 'forward looking statements' within the meaning of applicable laws and regulations. Certain observations made on the industry and other players also reflect on opinion by the management and the management accepts no liability on such opinions. Actual results might differ materially from those either expressed or implied.

INDEPENDENT AUDITOR'S REPORT**To the Members of
VANTA BIOSCIENCE LIMITED**

Report on the Audit of the Standalone Financial Statements

Opinion:

We have audited the standalone financial statements of Vanta Bioscience Limited which comprise the Balance Sheet as at 31st March 2019, the statement of Profit and Loss, statement of changes in equity, statement of cash flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- a) In the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2019;
- b) In the case of the Profit and Loss Account, of the profit for the period ended on that date and
- c) In the case of the cash flow statement, of the Cash Flows, for the period ended on that date.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules there under; and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters:

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

During the year, the Company acquired 20,00,000 shares at an issue price of Rs.10 per share of Vanta Clinical Research Limited. Vanta Clinical Research Limited is a wholly owned subsidiary Company of Vanta Bioscience Limited. The investment is shown at cost in the Balance sheet of Vanta Bioscience Limited.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon:

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors' Report and the annexures thereto, but does not include the standalone financial statements and our auditor's report thereon. The Directors Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. When we read the Directors' Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and describe actions applicable in the applicable laws and regulations.

Management's Responsibility for the Standalone Financial Statements:

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of

the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error; and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error; design and perform audit procedures responsive to those risks; and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements:

- 1) As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government

of India in terms of sub-section (11) of section 143 and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanation given to us, we give "Annexure-A" a statement on the matters specified in the paragraphs 3 and 4 of the Order to the extent applicable to the company.

- 2) As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
 - (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st March, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) In our opinion and to the best of our information and according to the explanations given to us, we are of the opinion that the company has adequate internal financial controls system in place and the operating effectiveness of such controls. Refer to our separate report in "Annexure - B".
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no such amounts which were required to be transferred to the Investor Education and Protection Fund by the Company. There has been no delay in transferring to the Investor Education and Protection Fund by the Company.
- 3) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its Directors during the year is in accordance with the provisions of Section 197 read with Schedule V to the Act and is not in excess of the limit laid down under this Section and Schedule V of the Act.

For **MATHESH & RAMANA**
 CHARTERED ACCOUNTANTS
 FRN : 002020S

Sd/-
B.V. RAMANA REDDY
 M. No. 026967 Partner

Place: Hyderabad
 Date: 22.05.2019

ANNEXURE A TO INDEPENDENT AUDITOR'S REPORT

Re: VANTA BIOSCIENCE LIMITED

Referred to in Paragraph 1 under section (Report on other Legal and Regulatory Requirements of our Report of even date)

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) The Company has a regular programme of physical verification of its fixed assets by which fixed assets are verified in a phased manner over a period of three years. In accordance with this programme, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
- (ii) (a) The Management has conducted physical verification of inventory (excluding stocks lying with third parties) at reasonable intervals. In respect of inventory lying with third parties, these have substantially been confirmed by them. In our opinion, the frequency of verification is reasonable.
- (b) In our opinion and according to the information and explanations given to us, the procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the Company and nature of its business.
- (c) The Company is generally maintaining proper records of inventory. The discrepancies noticed on verification between physical stock and book records were not material in relation to the operations of the Company and the same have been properly dealt with in the books of account.
- (iii) (a) The company has not granted loans to the parties covered in the register maintained under section 189 of the Companies Act, 2013. Therefore, the requirements of sub-clause (a), (b) and (c) of clause (iii), are not applicable to the Company.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- (v) According to the information and explanations given to us, the Company has not accepted any deposits in terms of directives issued by Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Companies Act and the rules framed there under.
- (vi) In our opinion and according to the information and explanations given to us, the company is not required to maintain cost records as required by sub section (1) of section 148 of the Companies Act, 2013 for the activities of the Company.
- (vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, income-tax, value added tax, duty of customs, service tax, cess and other material statutory dues have been regularly deposited during the year by the Company with the appropriate authorities. As explained to us, the Company did not have any dues on account of employees' state insurance and duty of excise. According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, income tax, value added tax, duty of customs, service tax, cess and other material statutory dues were in arrears as at 31 March 2019 for a period of more than six months from the date they became payable.
- (b) According to the information and explanations given to us, there are no material dues of duty of customs which have not been deposited with the appropriate authorities on account of any dispute.

- (c) According to the information and explanation given to us, there are no dues of sales tax, income tax and excise duty which have not been deposited on account of any dispute.
- (viii) The Company has not defaulted in repayment of any loans or borrowings from any financial institution, banks, government or debenture holders during the year.
- (ix) In our opinion and according to the information and explanations given to us, no money was raised by way of further public offer (including debt instruments) and term loans.
- (x) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- (xi) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- (xii) In our opinion and according to the information and explanations given to us, the company is not a nidhi company. Accordingly, paragraph 3(xii) of the order is not applicable.
- (xiii) According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has made a preferential allotment of 5,84,000 Equity Share of Rs. 10/- each at a premium of Rs. 75/- during the year.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. pursuant to the provisions of section 192 of the Companies Act, 2013. Accordingly, paragraph 3(xv) of the Order is not applicable.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS
 FRN : 002020S

Sd/-
B.V. RAMANA REDDY
 M. No. 026967 Partner

Place: Hyderabad
 Date: 22.05.2019

ANNEXURE B TO INDEPENDENT AUDITOR'S REPORT**Re: VANTA BIOSCIENCE LIMITED****Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of VANTA BIOSCIENCE LIMITED ("the Company") as of 31st March 2019 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls:

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility:

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting:

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting:

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion:

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS
FRN : 002020S

Sd/-
B.V. RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad

Date: 22.05.2019

BALANCE SHEET AS AT 31.03.2019

Particulars	Note No	As at 31.03.2019	As at 31.03.2018
1. Equity and Liabilities			
I. Share holder's Funds			
a) Share Capital	3	6,31,20,000	5,72,80,000
b) Reserves & Surplus	4	15,93,30,506	10,85,92,928
		22,24,50,506	16,58,72,928
II. Non Current Liabilities			
a) Deferred Tax Liabilities (Net)	5	40,25,642	22,76,497
b) Long Term Borrowings	6	12,16,62,774	9,98,00,532
c) Other Long Term Liabilities		-	-
d) Long Term Provisions		-	-
		12,56,88,416	10,20,77,029
III. Current Liabilities			
a) Short Term Borrowings	7	-	49,85,004
b) Trade Payables	8	45,73,210	19,42,585
c) Other Current Liabilities	9	2,60,99,864	1,64,33,898
d) Short Term Provisions	10	12,17,310	2,98,429
		3,18,90,384	2,36,59,916
Total		38,00,29,306	29,16,09,873
2. Assets			
I. Non Current Assets			
a) Fixed Assets			
Tangible Assets	11	16,73,58,922	14,97,10,128
Research & Development	11	4,86,22,591	4,86,22,591
b) Non Current Investments	12	2,00,00,000	-
c) Deferred Tax Assets(Net)		-	-
d) Long Term Loans and Advances		-	-
e) Other Non Current Assets	13	35,04,070	35,04,070
		23,94,85,583	20,18,36,789
II. Current Assets			
a) Current Investments	14	1,95,00,000	4,50,00,000
b) Inventories	15	9,24,42,123	3,02,44,486
c) Trade Receivables	16	1,56,39,950	33,02,389
d) Cash & Cash Equivalents	17	28,43,450	8,73,231
e) Short Term Loans & Advances	18	89,61,582	51,73,198
f) Other Current Assets	19	11,56,618	51,79,780
		14,05,43,723	8,97,73,084
Total		38,00,29,306	29,16,09,873

See accompanying notes to the financial statements

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants
 FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-
B.V. Ramana Reddy
 M.No. 026967 Partner

Sd/-
M.Dopesh Raja
 Managing Director
 DIN.NO.01176660

Sd/-
S.Venkat Rao
 Whole Time Director
 DIN.NO.02906370

Place: Hyderabad
 Date : 22/05/2019

Sd/-
Zoheb S Sayani
 Company Secretary
 M.No. A32277

Sd/-
A. Kiran Kumar
 CFO

Statement of Profit & Loss for year ended 31.03.2019

Particulars	Note No	For the Current year ended 31.03.2019	For the Previous year ended 31.03.2018
Revenue			
a) Revenue from Operations	20	12,42,47,982	3,98,59,588
b) Other Income	21	22,88,683	5,27,591
Total Revenue		12,65,36,666	4,03,87,179
Expenses			
a) Cost of material consumed	22	1,39,80,342	32,26,018
b) Purchases of Stock in Trade		-	-
c) Changes in Inventories: Work in Progress		-	-
d) Employee Benefit Expenses	23	4,15,39,315	1,61,11,250
e) Finance Cost	24	1,68,85,188	19,63,764
f) Depreciation and Amortization Expenses	25	71,09,609	57,21,662
g) Other Expenses	26	3,60,46,132	1,02,14,908
Total Expenses		11,55,60,585	3,72,37,602
Profit Before Tax		1,09,76,081	31,49,577
Tax Expenses			
a) Current Tax		22,89,357	6,00,152
b) Deferred Tax	5	17,49,145	22,76,497
Total		40,38,502	28,76,649
Net profit for the year		69,37,578	2,72,928
Earning per Equity Share			
1. Basic		1.17	0.05
2. Diluted		1.17	0.05

See accompanying notes to the financial statements

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants
 FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-
B.V. Ramana Reddy
 M.No. 026967 Partner

Sd/-
M.Dopesh Raja
 Managing Director
 DIN.NO.01176660

Sd/-
S.Venkat Rao
 Whole Time Director
 DIN.NO.02906370

Place: Hyderabad
 Date : 22/05/2019

Sd/-
Zoheb S Sayani
 Company Secretary
 M.No. A32277

Sd/-
A. Kiran Kumar
 CFO

Cash Flow statement for the year ended 31.03.2019

Particulars	Current Year 31.03.2019	Previous Year 31.03.2018
A. Cash Flow from Operating Activities		
Profit before exceptional , Extraordinary items and Tax	1,09,76,081	31,49,577
Adjustment for:		
Depreciation	71,09,609	57,21,662
Finance Charges	1,68,85,188	15,98,105
Gain/Loss on foreign Exchange fluctuation	-	6,611
Sub total	2,39,94,796	73,26,378
Operating profit Before Working Capital Changes	3,49,70,877	1,04,75,955
Adjustment for:		
(Increase) /Decrease in Inventories	-6,21,97,637	-3,02,44,486
(Increase) /Decrease in Trade recivables	-1,23,37,561	-33,08,999
Increase /(Decrease) in trade and payable	1,32,15,471	1,04,17,360
(Increase) /Decrease Loans & Advances	2,34,779	-98,49,671
(Increase) /Decrease in Current Investment	2,55,00,000	-4,50,00,000
Sub total	-3,55,84,948	-7,79,85,796
Cash Generated from operations	-6,14,071	-6,75,09,841
Net Cash Flow from Operarting Activities	-6,14,071	-6,75,09,841
B. Cash Flow from Investing Activities		
Purchase of Fixed Assets	-2,47,58,403	-2,59,70,934
Capital Work In progress	-	-
Capital Work In progress-R&D	-	-4,86,22,591
proceeds from sale of Fixed Assets	-	-
Investment in Subsidiaries	-2,00,00,000	-
Purchase of other Non current Investments	-	-7,56,000
Net Cash Flow from Investing Activites	-4,47,58,403	-7,53,49,525
C. Cash Flow from Financing Activites		
Increase /(Decrease) in Unsecured Loan	-	-
Increase /(Decrease) in Working capital	-49,85,004	1,19,85,004
Increase /(Decrease) in Term Loan	2,18,62,242	2,48,00,532
Increase /(Decrease) in share capital	58,40,000	2,08,20,000
Increase /(Decrease) in share Premium	4,38,00,000	8,32,80,000
Finance Charges	-1,68,85,188	-15,98,105
Net Cash Flow from Financing Activities	4,96,32,050	13,92,87,431
Actual Payment of Income Tax	-22,89,357	-
D. Net Increase/Decrease in Cash and cash Equivalents	19,70,219	-35,71,935
Opening of Cash & Cash Equivalents	8,73,231	44,45,166
Closing Balance of Cash & Cash Equivalents	28,43,450	8,73,231

See accompanying notes to the financial statements

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants
 FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-
B.V. Ramana Reddy
 M.No. 026967 Partner

Sd/-
M.Dopesh Raja
 Managing Director
 DIN.NO.01176660

Sd/-
S.Venkat Rao
 Whole Time Director
 DIN.NO.02906370

Place: Hyderabad
 Date : 22/05/2019

Sd/-
Zoheb S Sayani
 Company Secretary
 M.No. A32277

Sd/-
A. Kiran Kumar
 CFO

NOTES FORMING PART OF FINANCIAL STATEMENTS:
NOTE No. 1: CORPORATE INFORMATION:

VANTA BIOSCIENCE LIMITED ("The Company") was incorporated as Private Limited Company on 29th April, 2016, subsequently it was converted as a Public Limited Company on 17th March, 2017 and thereafter it is listed with BSE SME and the CIN being L74999TG2016PLC109280. The Company presently engaged in the business of Preclinical Activities.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES:
a) Basis of Accounting:

The financial statements have been prepared and presented under the historic cost convention on accrual basis to comply in all material respects with the notified Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The Accounting Policies have been consistently applied by the Company and are consistent with those used in the previous year. All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Companies Act, 2013.

b) Use of Estimates:

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of Assets or Liabilities in the Future periods.

c) Property, Plant and Equipments:

Fixed assets are stated at cost less depreciation. All costs (excluding CENVAT, VAT and Subsidy), including financing costs till commencement of commercial production and adjustments arising from exchange rate variations relating to borrowings attributable to the fixed assets are capitalized.

d) Depreciation:

The Company has provided depreciation for all the assets using Straight Line method as per the provisions specified in the Schedule II of the Companies Act, 2013.

e) Inventories:

Inventories have been taken as valued and certified by the Management. The basis of valuation is as under:

Raw materials, Stores & Spares - at cost or net realizable value whichever is lower.

Finished goods - at cost or net realizable value on FIFO basis whichever is lower.

f) Retirement benefits:

(i) Company's contribution to provident fund is charged to Profit & Loss Account.

(ii) Provision has been made in accounts for the future payment of gratuity to the employees of the Company, Pursuant to the payment of Gratuity Act, 1972 however provision has not been made based on the actuarial valuation.

g) Revenue recognition:

Income from operations is accounted Inclusive of GST on accrual basis.

i) Dividend from investments is recognized when the right to receive the payment is established.

ii) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income-" in the statement of profit and loss.

iii) Revenue accrued, but not due at the end of financial year is recognized on proportionate completion basis in profit & Loss Account as per AS-7.

h) Investments:

Current Investments are valued at cost or market price whichever is lower and in the absence of market quotation, cost price is adopted. Long Term Investments are valued at cost.

i) R&D Expenditure:

Capital expenditure is included in the fixed assets and depreciation as per Company's policy.

Revenue expenditure is charged to profit & loss account of the year in which they are incurred and included in the respective heads of expenditure.

j) Borrowing Costs:

Borrowings costs that are directly attributable to the acquisition of qualifying assets are capitalized as part of cost of such asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.

k) Cash Flow Statement:

The Cash Flow Statement has been compiled with and is based on the Balance Sheet as at 31st March, 2019 and the related Profit and Loss Account for the year ended on that date. The Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard - 3 on Cash Flow statement issued by ICAI.

l) Accounting for Taxes on Income:

Current Tax: Provision for Current Income Tax is made on the basis of the taxable income for the year as determined in accordance with the provisions of Income Tax Act, 1961.

Deferred Tax: Deferred income tax is recognized, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. The tax effect is calculated on the accumulated timing differences at the year end based on tax rates and laws. Enacted or substantially enacted as of the Balance Sheet date.

m) Impairment of Assets:

The management assesses using external and internal sources whether there is any indication that an asset may be impaired. Impairment of an asset occurs where the carrying value exceeds the present value of cash flow expected to arise from the continuing use of the asset and its eventual disposal. The provision for impairment loss is made when recoverable amount of the asset is lower than the carrying amount.

n) Provisions and Contingent Liabilities and Contingent Assets:

Provisions in respect of present obligations arising out of past events are made in the accounts when reliable estimate can be made of the amount of obligations and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but if material, are disclosed in the notes to accounts. Contingent assets are not recognized or disclosed in the financial statements.

o) Cash and Cash Equivalents:

Cash and cash equivalents comprise of cash at bank and cash in hand. The Company considers all highly liquid investments with an original maturity of three months or less from date of purchase, to be cash equivalents.

p) Intangible Assets:

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Intangible assets are amortized as per Accounting Standard 26.

q) Earning per share:

Basic earnings per share are calculated by dividing the net profit for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The number of shares used in computing diluted earnings per share comprises the weighted average number of shares considered for deriving basic earnings per share and also the weighted average number of equity shares, which may be issued on the conversion of all dilutive potential shares, unless the results would be anti dilutive.

r) Foreign Currency Transactions:

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of the transaction. Net exchange gain or loss resulting in respect of foreign exchange translations settled during period is recognized in the profit & loss account except for the net exchange gain or loss on account of imported fixed assets, which is adjusted in the carrying amount of the related fixed assets. Foreign currency denominated current assets and current liabilities at the period end are translated at the period end exchange rates and the resulting net gain or loss is recognized in the profit & loss account, except for exchange difference related to fixed assets purchased from foreign countries is adjusted in the carrying amount of related fixed assets.

Notes forming part of Balance sheet and statement of profit & Loss

3. Share capital

Particulars	As at 31.03.2019		As at 31.03.2018	
	No. of Shares	Amount in Rs	No. of Shares	Amount in Rs
a) Share Capital				
Authorized	75,00,000	7,50,00,000	45,00,000	4,50,00,000
Equity Shares of Rs. 10 Each				
Issued, Subscribed and fully paid up	63,12,000	6,31,20,000	57,28,000	5,72,80,000
Equity Shares of Rs. 10 Each				
Total	63,12,000	6,31,20,000	57,28,000	5,72,80,000

B) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period

Particulars	As at 31.03.2019		As at 31.03.2018	
	No. of Shares	Amount in Rs	No. of Shares	Amount in Rs
Equity Shares Outstanding at the beginning of the year	57,28,000	5,72,80,000	36,46,000	3,64,60,000
Equity Shares issued during the year	5,84,000	58,40,000	20,82,000	2,08,20,000
Total	63,12,000	6,31,20,000	57,28,000	5,72,80,000

C) Terms/ Rights attached to Equity Shares

The company has only one class of equity shares having par value of Rs. 10 Per share. Each holder of equity share is entitled to one vote per share .

d) Details of share held by each share Holder holding more than 5% Equity Shares

Name of the Share holder	As at 31.03.2019		As at 31.03.2018	
	No. of Shares	Amount in Rs	No. of Shares	Amount in Rs
Mulakala Mohan krishna	34,85,500	3,48,55,000	34,85,500	3,48,55,000
Mulakala Dopesesh Raja	4,58,000	45,80,000	1,94,000	19,40,000
Total	39,43,500	3,94,35,000	36,79,500	3,67,95,000

4. Reserves & Surplus

Particulars	As at 31.03.2019	As at 31.03.2018
Share premium	15,21,20,000	10,83,20,000
General reserve		
Balance as per the last balance sheet	-	-
Add: transferred during the Year	-	-
Surplus in Profit & Loss Statement		
Balance as per the last balance sheet	2,72,928	-
Add: transferred during the Year	69,37,578	2,72,928
Total	15,93,30,506	10,85,92,928

Notes forming part of Balance sheet and statement of profit & Loss

5. Deferred Tax Liability

Particulars	As at 31.03.2019	As at 31.03.2018
Opening Balance	22,76,497	-
Add: During the Year	17,49,145	22,76,497
Deferred Tax Liability	40,25,642	22,76,497

6. Long term Borrowings

Particulars	As at 31.03.2019	As at 31.03.2018
Term Loan		
From Banks and from financial institutions		
Secured borrowings	13,24,62,774	10,68,00,532
unsecured borrowings	-	-
Less: Amount disclosed under the head other current Liabilities payable within 1 year	1,08,00,000	70,00,000
Total	12,16,62,774	9,98,00,532

- Term Loan from State bank of India is secured by the hypothecation of Plant & Machinery including Lab Equipment standing in the name of the Company and primary security of Plot No. K2 11th Cross, SIPCOT, Industrial Complex, Gummidipudi, Tamilnadu-601201
- Collateral Security of Module A123 Quatrant3, 5th Floor, Cyber Towers, Madhapur, Serlingampally, Rangareddy-500050 and Personal Gurantee of two directors Mr. Mulakala Mohan Krishna and Mr.Mulakala Dopesha Raja.

7. Short tem Borrowings

Particulars	As at 31.03.2019	As at 31.03.2018
Unsecured loans		
Loan from Director	-	-
Secured loans		
Working Capital	-	49,85,004
Total	-	49,85,004

The working capital loan is secured by way of hypothecation of stocks, Books Debts, first charge on movable fixed assets and further guranteed by the directors

8. Trade Payables

Particulars	As at 31.03.2019	As at 31.03.2018
Sundry Creditors for Material	45,73,210	19,42,585
Total	45,73,210	19,42,585

Notes forming part of Balance sheet and statement of profit & Loss

9. Other Current Liabilities

Particulars	As at 31.03.2019	As at 31.03.2018
Outstanding Interest on Term Loan	14,48,695	10,59,133
Current Maturity on Term Loan	1,08,00,000	70,00,000
Creditors for Expenses	49,66,156	19,70,197
Creditors for Capital Goods	6,93,924	15,79,641
Outstanding Liabilities	11,59,708	6,91,027
Salaries & Wages Payable	63,07,289	28,21,310
Statutory Liabilities Payable		
PF Payable	1,55,238	1,23,669
ESI Payable	10,728	14,755
Professional Tax Payable	38,813	68,239
GST Payable	-	68,788
TDS Payable	5,19,313	10,37,139
Total	2,60,99,864	1,64,33,898

10. Short term provisions

Particulars	As at 31.03.2019	As at 31.03.2018
Provision of Income Tax	22,89,357	6,00,152
Add: Interest on Income Tax	80,164	-
Less: TDS	11,52,211	3,01,723
Total	12,17,310	2,98,429

NOTE 11 FIXED ASSETS & DEPRECIATION :

(Fig. In. Rs.)

DESCRIPTION	As on 01-04-2018	GROSS BLOCK			DEPRECIATION				NET BLOCK		
		During the Year		Capitalisation of Preoperative Expenses	Total as on 31/03/2019	As on 31-Mar-18	For the Year	Adjustments/ Deletions	Total as on 31-Mar-19	As on 31-Mar-19	As on 31-Mar-18
		Additions	Deletions								
Tangible Assets:											
LAND	1,17,50,795	-	-	-	1,17,50,795	-	-	-	-	1,17,50,795	1,17,50,795
BUILDING	5,88,33,306	11,83,939	-	-	6,00,17,246	13,94,781	18,81,812	-	32,76,593	5,67,40,652	5,74,38,525
PLANT & MACHINERY	2,63,32,187	25,01,765	-	-	2,88,33,952	12,50,779	17,06,802	-	29,57,581	2,58,76,372	2,50,81,408
LAB EQUIPMENT	91,43,717	62,71,707	-	-	1,54,15,424	6,51,490	11,64,414	-	18,15,904	1,35,99,519	84,92,227
MISC. FIXED ASSETS	13,12,945	2,17,034	-	-	15,29,979	92,886	1,38,558	-	2,31,444	12,98,535	12,20,059
COMPUTERS	8,22,271	5,60,766	-	-	13,83,037	6,27,783	3,43,592	-	9,71,375	4,11,662	1,94,488
ELECTRICAL EQUIPMENT	86,56,601	1,32,200	-	-	87,88,801	8,85,411	8,33,942	-	17,19,353	70,69,448	77,71,190
FURNITURE & FITTINGS	1,51,64,221	3,23,130	-	-	1,54,87,351	8,18,533	10,40,489	-	18,59,022	1,36,28,329	1,43,45,688
Capital Work in Progress	2,34,15,748	1,35,67,862	-	-	3,69,83,610	-	-	-	-	3,69,83,610	2,34,15,748
TOTAL	15,54,31,791	2,47,58,403	-	-	18,01,90,194	57,21,662	71,09,609	-	1,28,31,272	16,73,58,922	14,97,10,128
Previous Year	12,94,60,857	2,59,70,934			15,54,31,791	-	57,21,662	-	57,21,662	14,97,10,129	12,94,60,857
Intangible Assets:											
Research & Development	4,86,22,591		-		4,86,22,591	-	-	-	-	4,86,22,591	4,86,22,591
Total	4,86,22,591	-	-	-	4,86,22,591	-	-	-	-	4,86,22,591	4,86,22,591
Previous Year	-	4,86,22,591	-	-	4,86,22,591	-	-	-	-	4,86,22,591	-

Notes forming part of Balance sheet and statement of profit & Loss

12. Long Term Investments

Particulars	As at 31.03.2019	As at 31.03.2018
Equity shares 20,00,000@10/- in Vanta Clinical "Research Limited "	2,00,00,000	-
Total	2,00,00,000	-

13. Other Non Current Assets

Particulars	As at 31.03.2019	As at 31.03.2018
Electricity Deposit	27,48,070	27,48,070
Security Deposit with BSE	7,56,000	7,56,000
Total	35,04,070	35,04,070

14. Current Investments

Particulars	As at 31.03.2019	As at 31.03.2018
Investments in Mutual Funds	1,95,00,000	4,50,00,000
Total	1,95,00,000	4,50,00,000

15. Inventories

Particulars	As at 31.03.2019	As at 31.03.2018
Services Under Process	9,14,15,961	2,73,69,030
Closing Stock of Material	10,26,162	28,75,456
Total	9,24,42,123	3,02,44,486

16. Trade Receivables

Particulars	As at 31.03.2019	As at 31.03.2018
a) Trade Receivables outstanding for a period exceeding six months from the date they are due for payment Unsecured, Considered Good	4,16,720	-
b) Other Trade Receivables Unsecured, Considered Good	1,52,23,230	33,02,389
Total	1,56,39,950	33,02,389

Notes forming part of Balance sheet and statement of profit & Loss

17. Cash & Cash Equivalents

Particulars	As at 31.03.2019	As at 31.03.2018
In Current Accounts	23,08,493	3,47,229
Cash on Hand	5,34,957	5,26,002
Total	28,43,450	8,73,231

18. Short Term Loans & Advances

Particulars	As at 31.03.2019	As at 31.03.2018
Advance for Capital Goods	3,45,786	2,96,623
Staff Advance - Salary	5,04,993	5,25,640
Staff Advance - Expenses	-	15,090
GST Input Credit	81,10,802	43,35,845
Total	89,61,582	51,73,198

19. Other Current Assets

Particulars	As at 31.03.2019	As at 31.03.2018
Prepaid Expenses	1,96,334	3,56,318
Misc Exp not written off	-	6,62,290
IPO Expenses	-	36,33,581
Gain on Mutual Fund Units	9,60,283	5,27,591
Total	11,56,618	51,79,780

Notes forming part of Balance sheet and statement of profit & Loss

20. Revenue from Operations

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Revenue from Testing Analysis Service Charges(Domestic)	2,25,89,115	71,61,301
Revenue from Testing Analysis Service charges(Export)	3,76,11,936	53,29,257
Service Executed Bills Under process		
Unbilled Revenue	6,40,46,931	2,73,69,030
Total	12,42,47,982	3,98,59,588

21. Other Income

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Gain in Sale of Investment	22,88,683	5,27,591
Total	22,88,683	5,27,591

22. Consumption of Material

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Opening Stock of Materials	28,75,456	-
Add: Purchases		
Purchase of Lab Chemicals	32,29,334	20,90,917
Feed Cost	15,49,329	12,89,880
Purchase of Consumables	35,75,792	24,63,852
Purchase of Live Animals	21,61,850	1,55,700
Testing Charges	16,14,742	1,01,125
Sub Total	1,50,06,504	61,01,474
Less: Closing Stock	10,26,162	28,75,456
Total	1,39,80,342	32,26,018

Notes forming part of Balance sheet and statement of profit & Loss

23. Employment Benefit Expenses

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Salaries & Wages	2,46,49,200	1,20,85,698
Director Remuneration	1,21,89,579	-
Staffwelfare Expenses	12,01,961	14,45,447
Insurance to Employees	2,95,994	3,22,724
Contribution to PF	8,52,970	7,99,170
Contribution to ESI	1,13,841	1,25,017
Leave Encashment	7,04,891	8,876
Labour Charges	15,30,879	13,24,318
Total	4,15,39,315	1,61,11,250

24. Finance Cost

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Interest on Working Capital Loan	5,65,581	1,10,181
Interest on Term Loan	1,52,80,879	14,87,924
Interest on Others	78,660	69,205
Interest on Income Tax	80,164	
Bank Charges	1,27,583	1,43,954
Loan Processing Fee	7,52,321	1,52,500
Total	1,68,85,188	19,63,764

25. Depreciation and Amortisation Expenses

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Depreciation	71,09,609	57,21,662
Total	71,09,609	57,21,662

26. Other Expenses

Particulars	For the Year ended 31.03.2019	For the Year ended 31.03.2018
Goods and Service Tax	34,45,797	10,92,404
Electrical Maintenance	-	6,165
Factory Maintenance	7,83,460	5,00,840
Lab Maintenance	1,39,940	6,14,798
Repairs & Maintenance - P&M	8,28,312	14,000
Repairs & Maintenance - Others	2,16,026	1,18,948
Diesel Charges	10,29,412	4,86,600
Electricity Charges	87,50,532	13,88,403
Advertisement Expenses	3,09,832	25,000
Rent	57,340	54,000
Audit Fee	2,25,000	2,25,000
Audit Expenses	9,141	2,094
Books & Periodicals	3,346	2,270
Business Development Expenses	18,45,226	2,068
Commission	18,10,344	-
Computer Expenses	1,01,519	54,156
Consultancy Charges	25,06,115	-
Conveyance	4,25,711	2,20,485
Director's Sitting Fee	2,32,500	1,80,000
General Expenses	2,04,658	25,404
Insurance	58,675	75,469
Internet Expenses	3,79,506	5,61,437
Legal Expenses	80,000	-
Office Maintenance	3,31,985	51,074
Postage & Telegrams	1,12,693	43,265
Printing & Stationery	4,79,908	2,04,936
Rates & Taxes	1,92,921	2,77,460
Registration & Renewals	1,35,180	40,250
Safety Expenses	6,48,666	2,81,899
Security Expenses	10,07,380	11,35,139
Staff Recruitment Expenses	2,50,870	5,67,104
Subscription & Membership Fee	25,000	2,360
Telephone Expenses	2,83,243	2,99,497
Travelling Expenses	17,17,640	1,95,112
Vehicle Hire Charges	27,42,202	5,45,400
Lodging & Boarding Expenses	1,51,834	-
Vehicle Maintenance	-	6,865
Foreign Exchange Fluctuation	2,28,347	6,611
IPO Expenses Written Off	42,95,871	9,08,395
Total	3,60,46,132	1,02,14,908

27. FOREIGN EXCHANGE TRANSACTIONS:

	Particulars	31 March 2019 Rupees
a.	Value of imports	1,26,96,698
b.	Expenditure on Foreign Currency	14,17,008
c.	Earnings on Foreign Currency	3,76,11,936
d.	Foreign Exchange Loss	2,28,347

28. MANAGERIAL REMUNERATION:

		31 March 2019 Rupees
1.	Sri. M. Dopesha Raja	30,00,000
2.	Sri. Sadhanala Venkat Rao	60,00,000
3.	Dr. Vyas Murthy Madhava Rao	31,89,579

The above figures do not include Sitting fee paid and provision for gratuity and leave encashment.

29. REMUNERATION TO AUDITORS:

	31 March 2019 Rupees	31 March 2019 Rupees
A. Statutory Auditor:		
Statutory Audit Fee	1,25,000	
Tax Audit Fee	25,000	
Total A		1,50,000
B. Internal Auditor:		
Internal Auditor Fee	75,000	
Total B		75,000
Total (A) and (B)		2,25,000

30. DEFERRED TAX :

	31 March 2019 Rupees
In Conformity with the Accounting Standard 22 on Accounting for Taxes on income issued by Institute of Chartered Accountants of India, during the year the Company has provided for the Net Deferred Tax Liability/ Assets in the books of account.	
Net Block as per Companies Act	13,03,75,313
Net Block as per Income Tax Act	11,48,92,075
Timing Difference	1,54,83,238
Net Tax Liability as on 31-03-2019	40,25,642
Less: Deferred Tax Liability as on 31-03-2018	22,76,497
Effect on Profit and Loss Account (Deferred Tax for the year)	17,49,145

#Deferred Tax liability represents timing differences in depreciation on fixed assets.

31. EARNING PER SHARE:
(A) BASIC EARNING PER SHARE

i. Number of equity shares outstanding at the beginning of the year.	57,28,000
ii. Number of equity shares issued during the year.	5,84,000
iii. Total number of equity shares outstanding at the end of the year.	63,12,000
iv. Profit available to share holders.	69,37,578
v. Basic Earning per Share. (face value Rs. 10/-)	1.17

(B) DILUTED EARNING PER SHARE

i. Number of equity shares outstanding as per Point No. iii above.	63,12,000
ii. Weighted average number of potential equity shares outstanding	NIL
iii. Weighted average number of shares outstanding	63,12,000
iv. Profit available to share holders	69,37,578
v. Basic Earning per Share (face value Rs. 10/-)	1.17

32. RELATED PARTY TRANSACTIONS:

Disclosure as required by Accounting Standard AS 18: Related party disclosures issued by the Institute of Chartered Accountant of India (ICAI) are as follows:

S. No.	Name of the Related Party	Relation	Nature of Transaction	Volume of Transaction(Rs)	Closing Balance as on 31/03/2019(Rs)
1.	Sarvotham Solutions Ltd.	Two Promoter Directors are the shareholders	Consulting Services for Technical Due Diligence	6,11,316/-	-NIL-
2.	M. Sujana Sheela	Promoter's Spouse	Office Rent	54,000/-	54,000/-
3.	Vayam Research Solutions Ltd	Sister Concern	Testing & Analysis Charges and Expenses incurred on behalf Vayam Research Solutions Limited	4,05,000/- & 3,28,786/-	76,214/-
4.	Vanta Clinical Research Ltd.	Subsidiary Company	Testing & Analysis Charges and Expenses incurred on behalf of Vanta Clinical Research Limited.	3,15,000/- & 2,57,079/-	57,921/-
5.	Sri. M. Dopesha Raja	KMP	Key Managerial Personal Compensation	30,00,000/-	30,00,000/-
6.	Sri. Sadhanala Venkata Rao	KMP	Key Managerial Personal Compensation	60,00,000/-	60,00,000/-
7.	Sri Vyas Murthy Madhava Rao	KMP	Key Managerial Personal Compensation	31,89,579/-	31,89,579/-
8.	Sri. Zoheb Sayani	KMP	Key Managerial Personal Compensation	2,40,000/-	2,40,000/-

33. SEGMENT REPORTING:

The Company is engaged in the business of full service preclinical contract research organization. Accounting Standard 17 "Segment Reporting" issued by the Institute of Chartered Accountants of India is not applicable.

34. SHARE CAPITAL:

The authorized capital of the company is Rs. 7,50,00,000/- divided into 75,00,000 equity shares of Rs. 10/- each.

Total Paid up Equity Share Capital of Rs. 6,31,20,000/- are divided into 63,12,000 equity shares of Rs. 10/- each.

35. The cash balance as on 31/03/2019 amounts to Rs.5,34,957/-. Since we could not undertake physical verification of cash on 31/03/2019 we have relied upon the certificate issued by the management in this regard.

36. In the view of Management, no event has taken place to trigger the need for testing its assets for impairment. Accordingly, as per the management's assessment, the carrying values of its assets as at the Balance sheet date are not higher than their corresponding recoverable amounts.

37. In the opinion of the Board the Current assets, Loans and advances are approximately of the value stated if realized in the ordinary course of the business. The provision for depreciation and all known liabilities are adequate and not in excess of the amount considered reasonably necessary.

38. Confirmation of balances has not been received from any of the Creditors, Debtors and for Loans & Advances, which are subject to reconciliation. Provision for doubtful debts, if any, in respect of the above and the consequential adjustment, if any, whether of revenue nature or otherwise, will be dealt accordingly.

39. DISCLOSURE UNDER MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006:

As regards to the compliance of provisions relating to the dues to Micro, Small and Medium Enterprises in terms of Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006, the Company has sent letters to the Creditors to confirm whether they are Micro, Small and Medium Enterprises. The Company is yet to receive the confirmations from them. Hence, the Company could not quantify the dues, if any to the Micro, Small and Medium Enterprises.

40. ADDITIONAL INFORMATION PURSUANT TO PARAGRAPHS 3 & 4 OF PART II OF SCHEDULE III TO THE COMPANIES ACT 2013, (AS CERTIFIED BY A DIRECTOR): NIL

41. The company has not proposed any dividend for the year under review.

42. During the year the following provisions were made:

Particulars	Rupees
Current Tax	22,89,357
Previous Year's Tax adjustment	-NIL-

43. The company's investments are stated at cost price in financial statements.

S. No	Name of the fund	No. of Units	Cost In Rupees	Market price In Rupees
1.	SBI MUTUAL FUNDS	7015.815	1,95,00,000	2,04,60,281

Investments were stated at cost price in the financial statement.

44. During the year, the Company acquired 20,00,000 shares at an issue price of Rs.10 per share of Vanta Clinical Research Limited. Vanta Clinical Research Limited. is a wholly owned subsidiary Company of Vanta Bioscience Limited. The investment is shown at cost in the Balance sheet of Vanta Bioscience Limited.
45. During the year the Company has made a preferential allotment of 5,84,000 Equity Share of Rs. 10/- each at a premium of Rs. 75/-.
46. Previous year figures have been regrouped and rearranged wherever necessary.
47. All the amounts are rounded off to the nearest rupee.

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants
 FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-
B.V. Ramana Reddy
 M.No. 026967 Partner

Sd/-
M.Dopesh Raja
 Managing Director
 DIN.NO.01176660

Sd/-
S.Venkat Rao
 Whole Time Director
 DIN.NO.02906370

Place: Hyderabad
 Date : 22/05/2019

Sd/-
Zoheb S Sayani
 Company Secretary
 M.No. A32277

Sd/-
A. Kiran Kumar
 CFO

INDEPENDENT AUDITOR'S REPORT

To the Members of

VANTA BIOSCIENCE LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion:

We have audited the accompanying consolidated financial statements of **VANTA BIOSCIENCE LIMITED** (hereinafter referred to as "the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2019, and the Consolidated Statement of Profit and Loss, Consolidated Statement of Cash Flows, the Consolidated Statement of changes in equity for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the Consolidated State of Affairs of the Company as at March 31, 2019, Consolidated Profit, its Consolidated Cash Flows and Consolidated Changes in equity for the year then ended.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters:

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Consolidated Financial Statements of the current period. These matters were addressed in the context of our audit of the Consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. During the period, there is no such matters are addressed to Those Charged with Governance.

During the year, the Company acquired 20,00,000 shares at an issue price of Rs.10 per share of Vanta Clinical Research Limited. Vanta Clinical Research Limited. is a wholly owned subsidiary Company of Vanta Bioscience Limited. The investment is shown at cost in the Balance sheet of Vanta Bioscience Limited.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon:

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors' Report and the annexures thereto, but does not include the financial statements and our auditor's report thereon. The Directors Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. When we read the Directors' Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and describe actions applicable in the applicable laws and regulations.

Responsibilities of Management and those charged with Governance for the Consolidated Financial Statements:

The Holding Company's Board of Directors are responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as "the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in

accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective board of directors of the company is responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group is also responsible for overseeing the Company's financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements:

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matters:

We did not audit the financial statements / financial information of two subsidiaries, whose financial statements / financial information reflect total assets of Rs.506.17 Lacs as at 31st March, 2019 and total revenues of Rs.8.08 Lacs and net cash flows amounting to Rs.298.19 Lacs for the year ended on that date, as considered in the consolidated financial statements. The consolidated financial statements also include the Group's share of Net Profit of Rs. 0.27 Lacs for the year ended 31st March 2019 as considered in the Consolidated Financial Statements in respect of the

Subsidiary whose financial statements / financial information have not been audited by us. These financial statements / financial information have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries, is based solely on the reports of the other auditors.

Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements / financial information certified by the Management.

Report on Other Legal and Regulatory Requirements:

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
 - (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
 - (d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act.
 - (e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2019 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, none of the directors of the Group Companies is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) There were no pending litigations which would impact the consolidated financial position of the Group.
 - (ii) The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
 - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its subsidiary companies.
 - (g) With respect to the adequacy of internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in Annexure A.
2. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company to its Directors during the year is in accordance with the provisions of section 197 of the Act read with Schedule V of the Act and is not in excess of the limit laid down under this section and Schedule. In the case of a subsidiary company incorporated in India, the managerial remuneration has not been paid or provided and accordingly, the requisite approvals mandated by the provisions of Section 197 read with Schedule V of the Act are not required.

For **MATHESH & RAMANA**
 CHARTERED ACCOUNTANTS
 FRN : 002020S

Sd/-
B.V. RAMANA REDDY
 M. No. 026967 Partner

Place: Hyderabad
 Date: 22.05.2019

ANNEXURE A TO INDEPENDENT AUDITOR'S REPORT

Re: VANTA BIOSCIENCE LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31st March, 2019, we have audited the internal financial controls over financial reporting of **VANTA BIOSCIENCE LIMITED** (hereinafter referred to as "the Holding Company") and have adopted the report on the internal financial controls over financial reporting issued by the respective auditors of its subsidiary companies, which are companies incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls:

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility:

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting:

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting:

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The internal financial controls over financial reporting of Subsidiaries have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated internal financial controls over financial reporting, included in respect of these subsidiaries and our report in terms of Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls insofar as it relates to the aforesaid subsidiaries, is based solely on the reports of the other auditors.

Opinion:

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MATHESH & RAMANA**
 CHARTERED ACCOUNTANTS
 FRN : 002020S

Sd/-
B.V. RAMANA REDDY
 M. No. 026967 Partner

Place: Hyderabad

Date: 22.05.2019

CONSOLIDATED BALANCE SHEET AS AT 31.03.2019

Particulars	Note No	As at 31.03.2019
1. Equity and Liabilities		
I. Share holder's Funds		
a) Share Capital	3	6,31,20,000
b) Reserves & Surplus	4	15,93,57,720
c) Minority Interest		98,13,915
		23,22,91,635
II. Non Current Liabilities		
a) Deferred Tax Liabilities (Net)	5	40,25,642
b) Long Term Borrowings	6	12,16,62,774
c) Other Long Term Liabilities		-
d) Long Term Provisions		-
		12,56,88,416
III. Current Liabilities		
a) Short Term Borrowings		-
b) Trade Payables	7	45,73,210
c) Other Current Liabilities	8	2,62,19,769
d) Short Term Provisions	9	12,31,761
		3,20,24,740
Total		39,00,04,791
2. Assets		
I. Non Current Assets		
a) Fixed Assets		
Tangible Assets	10	16,73,58,922
Research & Development	10	4,86,22,591
b) Non Current Investments		-
c) Deferred Tax Assets(Net)		-
d) Long Term Loans and Advances		-
e) Other Non Current Assets	11	35,04,070
		21,94,85,583
II. Current Assets		
a) Current Investments	12	1,95,00,000
b) Inventories	13	9,24,42,123
c) Trade Receivables	14	1,56,39,950
d) Cash & Cash Equivalents	15	3,26,62,721
e) Short Term Loans & Advances	16	91,17,796
f) Other Current Assets	17	11,56,618
		17,05,19,208
Total		39,00,04,791

See accompanying notes to the consolidated financial statements

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants

FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-

B.V. Ramana Reddy
M.No. 026967 Partner

Sd/-

M.Dopesh Raja
Managing Director
DIN.NO.01176660

Sd/-

S.Venkat Rao
Whole Time Director
DIN.NO.02906370

Sd/-

Zoheb S Sayani
Company Secretary
M.No. A32277

Sd/-

A. Kiran Kumar
CFO

Place: Hyderabad
Date : 22/05/2019

ANNUAL REPORT - 2018-19

Consolidated Statement of Profit & Loss for year ended 31.03.2019

Particulars	Note No	For the year ended 31.03.2019
Revenue		
a) Revenue from operations	18	12,42,47,982
b) Other Income	19	22,88,683
Total Revenue		12,65,36,666
Expenses		
a) Cost of material consumed	20	1,39,80,342
b) Purchases of Stock in Trade		-
c) Changes in Inventories: Work in Progress		-
d) Employee Benefit Expenses	21	4,15,39,315
e) Finance Cost	22	1,68,85,188
f) Depreciation and Amortization Expenses	23	71,09,609
g) Other Expenses	24	3,59,90,552
Total Exp		11,55,05,005
Profit Before Tax		1,10,31,661
Tax Expenses		
a) Current Income Tax		23,03,808
b) Deferred Tax	5	17,49,145
Total		40,52,953
Net profit for the year		69,78,707
Less: Minority Interest		13,915
Net profit for the year		69,64,792
Earning for Equity Share		
1. Basic		1.10
2. Diluted		1.10

See accompanying notes to the consolidated financial statements

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants

FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-

B.V. Ramana Reddy
M.No. 026967 Partner

Sd/-

M.Dopesh Raja
Managing Director
DIN.NO.01176660

Sd/-

S.Venkat Rao
Whole Time Director
DIN.NO.02906370

Sd/-

Zoheb S Sayani
Company Secretary
M.No. A32277

Sd/-

A. Kiran Kumar
CFOPlace: Hyderabad
Date : 22/05/2019

Consolidated Cash Flow statement for the year ended 31.03.2019

Particulars	For the Year Ended 31.03.2019
A. Cash Flow from Operating Activities	
Profit before exceptional , Extraordinary items and Tax	1,10,31,661
Adjustment for:	
Depreciation	71,09,609
Finance Charges	1,68,85,188
Sub total	2,39,94,796
Operating profit Before Working Capital Changes	3,50,26,457
Adjustment for:	
(Increase) /Decrease in Inventories	-6,21,97,637
(Increase) /Decrease in Trade recivables	-1,30,47,561
Increase /(Decrease) in trade payables	1,39,91,668
(Increase) /Decrease Loans & Advances	-96,53,276
(Increase) /Decrease current Investment	2,55,00,000
Sub total	-4,54,06,806
Cash Generated from operations	-1,03,80,349
Net Cash Flow from Operarting Activities	-1,03,80,349
B: Cash Flow from Investing Activities	
Purchase of Fixed Assets	-2,47,58,403
Investment in Subsidiaries	-3,01,99,960
Net Cash Flow from Investing Activites	-5,49,58,363
C: Cash Flow from Financing Activites	
Increase /(Decrease) in Unsecured Loan	98,00,000
Increase /(Decrease) in Working capital	-49,85,004
Increase /(Decrease) in Term Loan	2,18,62,242
Increase /(Decrease) in share capital	4,58,40,000
Increase /(Decrease) in share Premium	4,38,00,000
Finance Charges	-1,68,85,188
Net Cash Flow from Financing Activities	9,94,32,050
Actual Payment of Income Tax	-23,03,808
D: Net Increase/Decrease in Cash and cash Equivalents	3,17,89,530
Opening of Cash & Cash Equivalents	8,73,231
Closing Balance of Cash & Cash Equivalents	3,26,62,761

See accompanying notes to the financial statements

As per our report of even date annexed.

For Mathesh & Ramana**Chartered Accountants**

FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-

B.V. Ramana Reddy

M.No. 026967 Partner

Sd/-

M.Dopesh Raja

Managing Director

DIN.NO.01176660

Sd/-

S.Venkat Rao

Whole Time Director

DIN.NO.02906370

Sd/-

Zoheb S Sayani

Company Secretary

M.No. A32277

Sd/-

A. Kiran Kumar

CFO

Place: Hyderabad

Date : 22/05/2019

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31st MARCH, 2019**1. CORPORATE INFORMATION :**

Vanta Bioscience Limited ("The Company") was incorporated on 29th April 2016. The company is engaged in the business of Preclinical Activities.

Vanta Bioscience Limited has one subsidiary and one step subsidiary. The details are as given below.

- a. Vanta Clinical Research Limited – Wholly Owned Subsidiary of Vanta Bioscience Limited
- b. Vayam Research Solutions Limited - Subsidiary of Vanta Clinical Research Limited

These Companies are engaged in Research & Development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies as well as diagnostics and cosmetics including clinical research.

The list of subsidiaries considered in these financial statements with percentage of holding is as follows.

Name of the Subsidiary	Country of Incorporation	Percentage of Holding	Period of Consolidation
M/s. Vanta Clinical Research Limited	A wholly owned subsidiary of Vanta Bioscience Limited	100%	12.09.2018 to 31.03.2019
M/s. Vayam Research Solutions Limited	A subsidiary of Vanta Clinical Research Limited	51%	10.10.2018 to 31.03.2019

2. Summary of Significant Accounting Policies:**a. Basis of Preparation:**

These Consolidated Financial statements have been prepared to meet the requirements under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules, 2015. The consolidated financial statements of Vanta Bioscience Limited and its subsidiaries (as listed above) collectively referred to as the 'Group', have been prepared and presented under the historical cost convention, on the accrual basis of accounting, in accordance with the provisions of the Companies Act, 2013, to the extent considered necessary for the purpose of these accounts, and in accordance with the accounting principles generally accepted in India ('Indian GAAP') issued by the Institute of Chartered Accountants of India ('ICAI'), to the extent applicable. The financial statements are presented in Indian rupees rounded off to the nearest rupee.

The financial statements of the Company and its subsidiary have been combined on a line by line basis by adding together the book values of like items of assets, liabilities, income and expenses. Intra group balances and intra group transactions and resulting unrealized profits are eliminated in full. Unrealized losses resulting from intra group transactions are also eliminated unless cost cannot be recovered.

The Consolidated financial statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances.

All Assets and liabilities have been classified as current and non-current as per the Group's normal operating cycle and other criteria set out in Schedule III to the Companies Act, 2013.

b. Principles of Consolidation:

The consolidated financial statements have been prepared in accordance with Indian Accounting Standard 110 "Consolidated Financial statement" issued by the ICAI. The consolidated financial statements have been prepared on the following basis:

- i) The financial statements of the Parent company and its subsidiaries have been consolidated on a line-by-line basis by adding together the fair values of like items of assets, liabilities, income and expenses, after eliminating the intra-group balances/ transactions and resulting unrealized profits in full. Unrealized losses resulting from intra-group transactions have also been eliminated unless cost cannot be recovered, and are presented to the extent possible, in the same manner as the company's independent financial statements.

- ii) The excess of cost to the parent company of its investment in the subsidiary over the parent company's portion of equity at the date on which investment in the subsidiary is made, is recognized as Goodwill (on consolidation). When the cost to the parent of its investment in the subsidiary is less than the parent's company's portion of equity of the subsidiary at the date on which investment in the subsidiary is made, the difference is treated as Capital Reserve (on consolidation) in the consolidated financial statements.
- iii) The financial statements of the subsidiaries used in the consolidation are drawn up to the same reporting date as that of the parent company i.e. period ended 31st March, 2019.
- iv) Minority interest in the net assets of consolidated subsidiaries consists of the amount of equity attributable to the minority shareholders at the dates on which investments in the subsidiary companies are made and further movements in their share in the equity, subsequent to the dates of investments.
- c. **Use of Estimates:**
The preparation of the consolidated financial statements requires the management of the Group to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to the contingent liabilities as at the date of the financial statements and reported amounts of income and expense during the year. Management believes that estimates made in the preparation of consolidated financial statements are prudent and reasonable. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in current and future periods.
- d. **Property, Plant & Equipment:**
Fixed assets are stated at cost less depreciation. Cost includes freight, duties, taxes and incidental expenses related to acquisition and installation of the fixed assets. The expenses related to, and incurred during implementation period have been capitalized under the appropriate heads.
- e. **Depreciation:**
Depreciation on Fixed assets has been charged on straight-line method at the rates and the manner specified in schedule II to the companies act, 2013. The cost of plant materials including replantation expenses is being written off over a period of five years.
- f. **Inventories:**
Inventories have been taken as valued and certified by the Management. The basis of valuation is as under:
Raw materials, Stores & Spares - at cost or net realizable value whichever is lower.
Finished goods – at cost or net realizable value on FIFO basis whichever is lower.
- g. **Revenue Recognition:**
The company follows mercantile system of accounting and recognizes significant items of income and expenditure as and when they are incurred and accrued.
- h. **Retirement benefits:**
 - 1. Company's contribution to provident fund if any is charged to Profit & Loss Account.
 - 2. Provision has been made in accounts for the future payment of gratuity to the employees of the Company. But the Company has not complied with the actuarial valuation requirements of Gratuity as per the Accounting Standard.
- i. **Investments:**
Current Investments are valued at fair value. Long Term Investments are valued at fair value. The difference of Book Value and Fair Value is treated as Impairment Loss.
- j. **R&D Expenditure:**
Capital expenditure is included in the fixed assets and depreciation as per Company's policy.
Revenue expenditure is charged to profit & loss account of the year in which they are incurred is included in the respective heads of expenditure.

k. Borrowing Costs:

Borrowings costs that are directly attributable to the acquisition of qualifying assets are capitalized as part of cost of such asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.

l. Cash Flow Statement:

The Cash Flow Statement has been compiled from and is based on the Balance Sheet as at 31st March, 2018 and the related Profit and Loss Account for the year ended on that date. The Cash Flow Statement has been prepared under the indirect method as set out in the Indian Accounting Standard - 7 on Cash Flow statement issued by ICAI.

m. Accounting For Taxes On Income:

Current Tax: Provision for Current Income Tax is made on the basis of the taxable income for the year as determined in accordance with the provisions of Income Tax Act, 1961.

Deferred Tax: Deferred income tax is recognized, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. The tax effect is calculated on the accumulated timing differences at the year end based on tax rates and laws. Enacted or substantially enacted as of the Balance Sheet date.

n. Employee Stock Option Scheme:

The company accounts for equity settled stock options as per the accounting treatment prescribed by Securities and Exchange Board of India (share based employee benefits) Regulations, 2014 and the Guidance Note on Employee Share-based Payments issued by the Institute of Chartered Accountants of India.

o. Impairment of Assets:

The management assesses using external and internal sources whether there is any indication that an asset may be impaired. Impairment of an asset occurs where the carrying value exceeds the present value of cash flow expected to arise from the continuing use of the asset and its eventual disposal. The provision for impairment loss is made when recoverable amount of the asset is lower than the carrying amount.

p. Government Grants & Other Claims:

Revenue grants including subsidy/rebates, refunds, claims etc., are credited to profit & loss account under other income or deducted from the related expenses. Grants related to fixed assets are credited to capital reserves account or adjusted in the cost of such assets as the case may be, as and when the ultimate realisability of such grants etc., are established/realized.

q. Provisions and Contingent Liabilities and Contingent Assets:

Provisions in respect of present obligations arising out of past events are made in the accounts when reliable estimate can be made of the amount of obligations and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but if material, are disclosed in the notes to accounts. Contingent assets are not recognized or disclosed in the financial statements.

r. Cash and Cash Equivalents:

Cash and cash equivalents comprise of cash at bank and cash in hand. The Company considers all highly liquid investments with an original maturity of three months or less from date of purchase, to be cash equivalents.

s. Leases:

Lease rentals in respect of assets acquired under operating lease are charged to Statement of Profit and Loss.

t. Intangible Assets:

The expense incurred on the development of overseas markets has been recognized as Intangible Assets and will be amortized over a period of five years. The company is following the practice of writing off Deferred Revenue Expenses over a period of five years and the same accounting treatment is consistently

followed for the current year also. Any new deferred revenue expenditure incurred will be written off in the year of such expenditure as per Indian Accounting Standard 38.

u. Segment Reporting:

The accounting policies adopted for segment reporting are in conformity with the accounting policies adopted for the company. Further,

- (i) Inter segment revenue has been accounted for based on the transaction price agreed to between segments which is primarily market based.
- (ii) Revenue and expenses have been identified to segments on the basis of their relationship to the operating activities of the segment. Revenue and expenses, which relate to the company as a whole and are not allocable to segments on a reasonable basis, have been included under "Un-allocated corporate expenses net of un-allocated income".

v. Foreign Currency transactions:

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of the transaction. Net exchange gain or loss resulting in respect of foreign exchange transactions settled during the period is recognized in the profit and loss account except for the net exchange gain or loss on account of imported fixed assets, which is adjusted in the carrying amount of the related fixed assets. Foreign currency denominated current assets and current liabilities at period end are translated at the period end exchange rates and the resulting net gain or loss is recognized in the profit and loss account, except for exchange differences related to acquisition of fixed assets purchased from foreign countries is adjusted in the carrying amount of the related fixed assets.

w. Foreign Currency translation:

The consolidated financial statements are reported in Indian rupees. Since the company has the non-integral subsidiaries, assets and liabilities are translated at exchange rates prevailing at the date of the Balance sheet. The items in the Profit and loss account are translated at the average exchange rate during the period. The differences arising out of the transactions are transferred to Exchange translation reserve on consolidation of non-integral subsidiary, under Reserves and Surplus.

x. Earnings per share:

The basic earnings per equity share is computed by dividing the net profit or loss for the period attributable to the equity shareholders by the weighted average number of equity shares outstanding during the reporting period. The number of shares used in computing diluted earnings per share comprises the weighted average number of shares considered for deriving basic earnings per share, and also the weighted average number of equity shares, which may be issued on the conversion of all dilutive potential shares, unless the results would be anti-dilutive.

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

3. Share capital

Particulars	As at 31.03.2019	
	No. of Shares	Amount in Rs
a) Share Capital		
Authorized	75,00,000	7,50,00,000
Equity Shares of Rs. 10 Each		
Issued, Subscribed and fully paid up	63,12,000	6,31,20,000
Equity Shares of Rs. 10 Each		
Total	63,12,000	6,31,20,000

- B) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period

Particulars	As at 31.03.2019	
	No. of Shares	Amount in Rs
Equity Shares Outstanding at the beginning of the year	57,28,000	5,72,80,000
Equity Shares issued during the year	5,84,000	58,40,000
Total	63,12,000	6,31,20,000

- C) Terms/ Rights attached to Equity Shares

The company has only one class of equity shares having par value of Rs. 10 Per share. Each holder of equity share is entitled to one vote per share .

- d) Details of share held by each share Holder holding more than 5% Equity Shares

Name of the Shareholder	As at 31.03.2019	
	No. of Shares	Amount in Rs
Mulakala Mohan krishna	34,85,500	3,48,55,000
Mulakala Dopesh Raja	4,58,000	45,80,000
Total	39,43,500	3,94,35,000

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

4. Reserves & Surplus

Particulars	As at 31.03.2019
Share premium	15,21,20,000
General reserve	
Balance as per the last Balance Sheet	-
Add: transferred during the Year	-
Surplus in Profit & Loss Statement	
Balance as per the last Balance Sheet	2,72,928
Add: transferred during the Year	69,64,792
Total	15,93,57,720

5. Deferred Tax Liability

Particulars	As at 31.03.2019
Deferred Tax Liability	40,25,642

6. Long term Borrowings

Particulars	As at 31.03.2019
Term Loan	
From Banks and from financial institutions	
Secured Borrowings	13,24,62,774
Unsecured Borrowings	
Less: Amount disclosed under the head other current Liabilities payable within 1 year	1,08,00,000
Total	12,16,62,774

- a. Term loan from State bank of India is secured by the hypothecation of Plant & Machinery including lab equipment standing in the name of the company and primary security of Plot No. K2 11th Cross, SIPCOT, Industrial Complex, Gummidipudi, Tamilnadu-601201
- b. Collateral security of Module A123 Quatrant3,5th Floor, Cyber towers, Madhapur, Serlingam pally, Ranga reddy-500050 and Personal Gurantee of two directors Mr. Mulakala Mohan Krishna and Mr.Mulakala Dopesh Raja

7. Trade Payables

Particulars	As at 31.03.2019
Sundry Creditors for Material	45,73,210
Total	45,73,210

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

8. Other Current Liabilities

Particulars	As at 31.03.2019
Outstanding Interest on Term Loan	14,48,695
Current Maturity on Term Loan	1,08,00,000
Creditors for Expenses	50,76,061
Creditors for Capital Goods	6,93,924
Outstanding Liabilities	11,69,708
Salaries & Wages Payable	63,07,289
Statutory Liabilities Payable	-
PF Payable	1,55,238
ESI Payable	10,728
Professional Tax Payable	38,813
TDS Payable	5,19,313
Total	2,62,19,769

9. Short Term Provisions

Particulars	As at 31.03.2019
Provision of Income Tax	23,03,808
Add: Interest on Income Tax	80,164
Less: TDS	11,52,211
Total	12,31,761

NOTE 10 : FIXED ASSETS & DEPRECIATION :

(Fig. In. Rs.)

DESCRIPTION	As on 01-04-2018	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		During the Year		Capitalisation of Preoperative Expenses	Total as on 31/03/2019	As on 31-Mar-18	For the Year	Adjustments/ Deletions	Total as on 31-Mar-19	As on 31-Mar-19	As on 31-Mar-18
		Additions	Deletions								
Tangible Assets:											
LAND	1,17,50,795	-	-	-	1,17,50,795	-	-	-	-	1,17,50,795	1,17,50,795
BUILDING	5,88,33,306	11,83,939	-	-	6,00,17,246	13,94,781	18,81,812	-	32,76,593	5,67,40,652	5,74,38,525
PLANT & MACHINERY	2,63,32,187	25,01,765	-	-	2,88,33,952	12,50,779	17,06,802	-	29,57,581	2,58,76,372	2,50,81,408
LAB EQUIPMENT	91,43,717	62,71,707	-	-	1,54,15,424	6,51,490	11,64,414	-	18,15,904	1,35,99,519	84,92,227
MISC. FIXED ASSETS	13,12,945	2,17,034	-	-	15,29,979	92,886	1,38,558	-	2,31,444	12,98,535	12,20,059
COMPUTERS	8,22,271	5,60,766	-	-	13,83,037	6,27,783	3,43,592	-	9,71,375	4,11,662	1,94,488
ELECTRICAL EQUIPMENT	86,56,601	1,32,200	-	-	87,88,801	8,85,411	8,33,942	-	17,19,353	70,69,448	77,71,190
FURNITURE & FITTINGS	1,51,64,221	3,23,130	-	-	1,54,87,351	8,18,533	10,40,489	-	18,59,022	1,36,28,329	1,43,45,688
Capital Work in Progress	2,34,15,748	1,35,67,862	-	-	3,69,83,610	-	-	-	-	3,69,83,610	2,34,15,748
TOTAL	15,54,31,791	2,47,58,403	-	-	18,01,90,194	57,21,662	71,09,609	-	1,28,31,272	16,73,58,922	14,97,10,128
Intangible Assets:											
Research & Development	4,86,22,591	-	-	-	4,86,22,591	-	-	-	-	4,86,22,591	4,86,22,591
	4,86,22,591	-	-	-	4,86,22,591	-	-	-	-	4,86,22,591	4,86,22,591

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

11. Other Non Current Assets

Particulars	As at 31.03.2019
Electricity Deposit	27,48,070
Security Deposit with BSE	7,56,000
Total	35,04,070

12. Current Investments

Particulars	As at 31.03.2019
Investments in Mutual Funds	1,95,00,000
Total	1,95,00,000

13. Inventories

Particulars	As at 31.03.2019
Services Under process	9,14,15,961
Closing Stock of Material	10,26,162
Total	9,24,42,123

14. Trade Receivables

Particulars	As at 31.03.2019
a) Trade Receivables outstanding for a period exceeding six months from the date they are due for payment Unsecured, considered good	4,16,720
b) Other Trade Receivables Unsecured, considered good	1,52,23,230
Total	1,56,39,950

15. Cash & Cash Equivalents

Particulars	As at 31.03.2019
In current Accounts	3,21,27,724
Cash on Hand	5,34,997
Total	3,26,62,721

16. Short Term Loans & Advances

Particulars	As at 31.03.2019
Advance for capital Goods	4,22,000
Staff Advance-Salary	5,04,993
GST Input Credit	81,10,802
TDS Receivable	80,000
Total	91,17,796

17. Other Current Assets

Particulars	As at 31.03.2019
Prepaid Expenses	1,96,334
Gain On Mutualfund Units	9,60,283
Total	11,56,618

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

18. Revenue from Operations

Particulars	For the Year ended 31.03.2019
Revenue from Testing Analysis Service Charges(Domestic)	2,25,89,115
Revenue from Testing Analysis Service charges(Export)	3,76,11,936
Service Executed Bills Under process	
Unbilled Revenue	6,40,46,931
Total	12,42,47,982

19. Other Income

Particulars	For the Year ended 31.03.2019
Gain in Sale of Investment	22,88,683
Total	22,88,683

20. Consumption of Material

Particulars	For the Year ended 31.03.2019
Opening Stock of materials	28,75,456
Add: Purchases	
Purchase of Lab chemicals	32,29,334
Feed Cost	15,49,329
Purchase of consumables	35,75,792
Purchase of Live animals	21,61,850
Testing Chages	16,14,742
Sub Total	1,50,06,504
Less: Closing Stock	10,26,162
Total	1,39,80,342

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

21. Employment Benefit Expenses

Particulars	For the Year ended 31.03.2019
Salaries & Wages	2,46,49,200
Director Remuneration	1,21,89,579
Staff Welfare Expenses	12,01,961
Insurance to Employees	2,95,994
Contribution to PF	8,52,970
Contribution to ESI	1,13,841
Leave Encashment	7,04,891
Labour Charges	15,30,879
Total	4,15,39,315

22. Finance Cost

Particulars	For the Year ended 31.03.2019
Interest on Working Capital Loan	5,65,581
Interest on Term Loan	1,52,80,879
Interest on Others	78,660
Interest on Income Tax	80,164
Bank Charges	1,27,583
Loan Processing Fee	7,52,321
Total	1,68,85,188

23. Depreciation and Amortisation Expenses

Particulars	For the Year ended 31.03.2019
Depreciation	71,09,609
Total	71,09,609

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

24. Other Expenses

Particulars	For the Year ended 31.03.2019
Goods and Service Tax	34,45,797
Factory Maintenance	7,83,460
Lab Maintenance	1,39,940
Repairs & Maintenance - P&M	8,28,312
Repairs & Maintenance - Others	2,16,026
Diesel Charges	10,29,412
Electricity Charges	87,50,532
Advertisement Expenses	3,09,832
Rent	57,340
Audit Fee	3,43,000
Audit Expenses	9,141
Books & Periodicals	3,346
Business Development Expenses	18,45,226
Commission	18,10,344
Computer Expenses	1,01,519
Consultancy Charges	17,06,115
Conveyance	4,25,711
Director's Sitting Fee	2,32,500
Filing Fees	5,38,572
General Expenses	2,04,658
Insurance	58,675
Internet expenses	3,79,506
Legal Expenses	80,000
Office Maintenance	3,31,985
Other Expenses	67,455
Postage & Telegrams	1,12,693
Printing & Stationery	4,79,908
Rates & Taxes	1,92,921
Registration & Renewals	1,35,180
Safety Expenses	6,48,666
Security Expenses	10,07,380
Staff Recruitment Expenses	2,50,870
Subscription & Membership Fee	25,000
Telephone Expenses	2,83,243
Travelling Expenses	17,38,033
Vehicle Hire charges	27,42,202
Lodging & Boarding Expenses	1,51,834
Foreign Exchange Fluctuation	2,28,347
IPO Expenses Written Off	42,95,871
Total	3,59,90,552

25. In the view of Management, no event has taken place to trigger the need for testing its assets for impairment. Accordingly, as per the management assessment, the carrying values of its assets as at the Balance sheet date are not higher than their corresponding recoverable amounts.

26. EARNINGS PER SHARE (EPS):

Particulars	Period Ended 31.03.2019
Profit attributed to the Equity Shareholders (Rs) (A)	69,64,792
Weighted average number of Equity Shares Outstanding during the year (B)	63,12,000
Face Value of Equity Shares (Rs)	10/-
Basic Earnings per share (Rs.)- (A/B)	1.10
Diluted Earnings per Share (Rs.) (A/B)	1.10

27. OPERATING SEGMENTS IND AS – 108:

The Company is engaged in the business of Preclinical Activities and is not engaged in any other kind of business. Hence segment reporting is not applicable.

RELATED PARTY TRANSACTIONS:

Disclosure as required by Accounting Standard AS 18: Related party disclosures issued by the Institute of Chartered Accountant of India (ICAI) are as follows:

S. No.	Name of the Related Party	Relation	Nature of Transaction	Volume of Transaction(Rs)	Closing Balance as on 31/03/2019(Rs)
1.	Sarvatham Solutions Ltd.	Two Promoter Directors are the shareholders	Consulting Services for Technical Due Diligence	6,11,316/-	-NIL-
2.	M. Sujana Sheela	Promoter's Spouse	Office Rent	54,000/-	54,000/-.
3.	Vayam Research Solutions Ltd	Sister Concern	Testing & Analysis Charges and Expenses incurred on behalf Vayam Research Solutions Limited	4,05,000/- & 3,28,786/-	76,214/-
4.	Vanta Clinical Research Ltd.	Subsidiary Company	Testing & Analysis Charges and Expenses incurred on behalf of Vanta Clinical Research Limited.	3,15,000/- & 2,57,079/-	57,921/-
5.	Sri. M. Dopesha Raja	KMP	Key Managerial Personal Compensation	30,00,000/-	30,00,000/-
6.	Sri. Sadhanala Venkata Rao	KMP	Key Managerial Personal Compensation	60,00,000/-	60,00,000/-
7.	Sri. Vyas Murthy Madhava Rao	KMP	Key Managerial Personal Compensation	31,89,579/-	31,89,579/-
8.	Sri. Zoheb Sayani	KMP	Key Managerial Personal Compensation	2,40,000/-	2,40,000/-

28. In compliance with Indian Accounting Standard – IND AS 17 “Leases”, the following are the Disclosures: NIL.

29. CONTINGENT LIABILITIES: NIL.

30. MANAGERIAL REMUNERATION:

	31 March 2019 Rupees
1. Sri. M.DOPESH RAJA	30,00,000
2. Sri. SADHANALA VENKAT RAO	60,00,000
3. Dr. VYAS MURTHY MADHAVA RAO	31,89,579

The above figures do not include Sitting fee paid and provision for gratuity and leave encashment.

32. AUDITOR'S REMUNERATION:

	31 March 2019 Rupees	31 March 2019 Rupees
A. Statutory Auditor:		
Statutory Audit Fee	2,43,000	
Tax Audit Fee	25,000	
Total A		2,68,000
B. Internal Auditor:		
Internal Auditor Fee	75,000	
Total B		75,000
Total (A) and (B)		3,43,000

33. In compliance with Indian Accounting Standard (IND AS – 12) “Income Taxes” issued by the Institute of Chartered Accountants of India, the company provided for deferred taxes on timing differences in the books.

Particulars	31 March 2019 Rupees
In Conformity with the Accounting Standard 22 on Accounting for Taxes on income issued by Institute of Chartered Accountants of India, during the year the Company has provided for the Net Deferred Tax Liability/ Assets in the books of account.	
Net Block as per Companies Act	13,03,75,313
Net Block as per Income Tax Act	11,48,92,075
Timing Difference	1,54,83,238
Net Tax Liability as on 31-03-2019	40,25,642
Less: Deferred Tax Liability as on 31-03-2018	22,76,497
Effect on Profit and Loss Account (Deferred Tax for the year)	17,49,145

#Deferred Tax liability represents timing differences in depreciation on fixed assets.

34. In the opinion of the Board the Current assets, Loans and advances are approximately of the value stated if realized in the ordinary course of the business. The provision for depreciation and all known liabilities are adequate and not in excess of the amount considered reasonably necessary.
35. Confirmation of balances has not been received from any of the Creditors, Debtors and for Loans & Advances, which are subject to reconciliation. Provision for doubtful debts, if any, in respect of the above and the consequential adjustment, if any, whether of revenue nature or otherwise, will be dealt accordingly.
36. DISCLOSURE UNDER MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006:
As regards to the compliance of provisions relating to the dues to Micro, Small and Medium Enterprises in terms of Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006, the Company has sent letters to the Creditors to confirm whether they are Micro, Small and Medium Enterprises. The Company is yet to receive the confirmations from them. Hence, the Company could not quantify the dues, if any to the Micro, Small and Medium Enterprises.
37. Additional information pursuant to Part II of Schedule III of the Companies Act, 2013. Quantitative and other details: Not Applicable.
38. During the year the following provisions are made:
Current Tax - Rs. 23,03,808/-
39. Figures have been rounded off to the nearest rupee.

As per our report of even date annexed.

For Mathesh & Ramana
Chartered Accountants
FRN : 002020S

For and on behalf of the Board of Directors
Vanta Bioscience Ltd

Sd/-
B.V. Ramana Reddy
M.No. 026967 Partner

Sd/-
M.Dopesh Raja
Managing Director
DIN.NO.01176660

Sd/-
S.Venkat Rao
Whole Time Director
DIN.NO.02906370

Place: Hyderabad
Date : 22/05/2019

Sd/-
Zoheb S Sayani
Company Secretary
M.No. A32277

Sd/-
A. Kiran Kumar
CFO

VANTA BIOSCIENCE LIMITED**CIN:** L74999TG2016PLC109280**Address:** No.02/G/308/G NO.3/FF/SF/1-20-248, Umajay Complex Rasoolpura,
Secunderabad - 500003, Telangana**Tel No.:** +91 40 6657 5454, **Email ID:** cs@vantabio.com**ATTENDANCE SLIP**

3rd Annual General Meeting

(Please complete this attendance slip and hand it over at the entrance of the registered office)

I/ We hereby record my/ our presence at the 3rd Annual General Meeting of the Company held on Friday, September 27, 2019 at 11:00 A.M. at Twilight, 6th floor, Manasarovar The Fern - An Ecotel, U.S. Consulate Lane, Begumpet, Secunderabad 500 003, Telangana

Name of the Member/Proxy _____ Signature _____

Folio No. _____ No. of Shares Held _____

*DP ID _____ *Client ID _____

*Applicable to investors holding shares in Electronic Form

Notes:

1. Electronic copy of the Annual Report for 2019 and Notice of the Annual General Meeting along with Attendance Slip and Proxy Form is being sent to all the members whose email address is registered with the Company/ Depository Participant unless any member has requested for a hard copy of the same. Shareholders receiving electronic copy and attending the Annual General Meeting can print copy of this Attendance Slip.
2. Physical copy of the Annual Report for 2019 and Notice of the Annual General Meeting along with Attendance Slip and Proxy Form is sent in the permitted mode(s) to all members whose email ids are not registered with the Company or have requested for a hard copy.

VANTA BIOSCIENCE LIMITED

CIN: L74999TG2016PLC109280

Address: No.02/G/308/G NO.3/FF/SF/1-20-248, Umajay Complex Rasoolpura,
Secunderabad - 500003, Telangana

Tel No.: +91 40 6657 5454, **Email ID:** cs@vantabio.com

FORM NO. MGT - 11**PROXY FORM**

(Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014)

Name of the Member(s):

Registered Address:

E-mail ID:

Folio No. _____

No. of Shares Held _____

*DP ID _____

*Client ID _____

*Applicable to investors holding shares in Electronic Form

I/We, being the member(s) _____ Shares of Shares of the Company, hereby appoint:

1. Name : _____ Email ID: _____
Address : _____
Signature : _____ or failing him
2. Name : _____ Email ID: _____
Address : _____
Signature : _____ or failing him
3. Name : _____ Email ID: _____
Address : _____
Signature : _____

as my/ our proxy to attend and vote (on poll) for me/ us and on my/ our behalf at the 3rd Annual General Meeting of the Company to be held on Friday, September 27, 2019 at 11:00 A.M. at Twilight, 6th floor, Manasarovar The Fern - An Ecotel, U.S. Consulate Lane, Begumpet, Secunderabad - 500 003, Telangana and at any adjournment thereof in respect of such resolutions as are indicated below:

S. No.	Resolutions	For	Against
Ordinary Business			
1	To receive, consider and adopt the Standalone Audited Financial Statements for the financial year ended March 31, 2019 along with the Reports of the Auditors and Board of Directors thereon		
2	To receive, consider and adopt the Audited Consolidated Financial Statements for the financial year ended March 31, 2019 together with the Report of the Auditors thereon		
3	To appoint a Director in place of Mr. Sadhanala Venkata Rao (DIN: 02906370) who retires by rotation and being eligible, offers himself for re-appointment.		
4	Appointment of Dr. Yogeswara Rao Danda (DIN: 00694803) as an Independent Director.		

Please put a tick mark (✓) in the appropriate column against the resolutions indicated in the box. If a member leaves the "For" or "Against" column blank against any or all the Resolutions, the proxy will be entitled to vote in the manner he/she thinks appropriate. If a member wishes to abstain from voting on a particular resolution, he/she should write "Abstain" across the boxes against the Resolution.

Signed this _____ day of September, 2019

Signature of Member

Affix
Revenue
Stamp

**FORM FOR REGISTRATION OF EMAIL ADDRESS FOR RECEIVING DOCUMENTS/NOTICES BY
ELECTRONIC MODE**

To.

Bigshare Services Private Limited

RTA of Vanta Bioscience Limited

306, Right Wing, Amrutha Ville Apts. Somajiguda, Hyderabad - 500 082

Contact No. : 040 2337 4967

Sub: Registration of email address for receiving documents/notices by electronic mode

Ref: Vanta Bioscience Limited - Scrip Code: 540729 - ISIN: INE695X01011

I agree to receive all documents/notices and other correspondences and communications including the annual report from the Company in electronic mode. Please register my email address given below in your records for sending communication through email.

The following are my details

Name of Sole/First Holder:

DP ID Client ID/ Regd. Folio No:

PAN No.:

Email Address:

Phone No.

I request you to kindly update the same in your records. I instruct you to send all documents/notices and other correspondences and communications including annual report from the Company in electronic mode to the email id mentioned above.


Name: _____

Signature: _____

Date:

Place:

VENUE OF THE 3rd ANNUAL GENERAL MEETING OF VANTA BIOSCIENCE LIMITED



[illegible]

THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY